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ABSTRACT

The use of targeted ligands to deliver radioisotopes directly to tumor cells is a promising
therapeutic strategy. Because of the short path length and high LET of alpha particles, targeted
alpha particles are ideal for treating metastatic disease while minimizing damage to non-targeted
tissues. However, clinical methods for determining 3D radiation dosimetry in patients with
multiple metastatic lesions are needed to support clinical translation of novel targeted alpha
particle therapies for personalized treatment, especially in patients that have previously received
radiotherapy. Recently interest in novel radiopharmaceutical development has grown
significantly. However, compared to external beam radiation therapy, progress in customizing
radiopharmaceutical treatments specific to the patient has remained stagnant for decades.
Currently, therapies are given using fixed dose administrations and dosimetry is performed using
outdated simplistic representations of a standard human. The potential benefits of targeted alpha
therapies cannot be taken advantage of until pretreatment planning is employed to optimize each
patient’s therapy on an individual basis. Dose response relationships need to be analyzed posttreatment to assess tumor control probabilities and normal tissue complications. With new
developments in medical imaging and instrumentation, along with the continuously increasing
computational power available, personalized targeted alpha therapies can be achieved.
In this work, a novel targeted alpha therapy for treatment of metastatic uveal melanoma,
225

Ac-DOTA-MC1RL, is developed and thoroughly tested pre-clinically. The therapy showed

x

rapid eradication of tumors with no normal tissue toxicity with a single administration. Radiation
detection instrumentation is improved upon by developing a method to more accurately quantify
radioactivity for administration, biodistribution, pharmacokinetics, and dosimetry. A voxel-based
Monte Carlo dosimetry methodology is developed using a novel companion imaging agent in
both phantom and in vivo pre-clinical imaging studies. From these studies, a clinically
translatable workflow is described and tested. 3D dosimetry calculations were performed
enabling volumetric dose analysis for the novel therapy.

xi

CHAPTER ONE:
INTRODUCTION

1.1 Overview
Advances in the understanding of molecular characteristics of cancerous cells have paved
the way for targeted radiopharmaceutical therapy. Identifying a malignant target and designing a
vehicle to deliver high doses of radiation has become a promising modality to treat cancer.
Recently, interest in using alpha emitting radioisotopes to selectively destroy the DNA of cancer
cells has increased. This is due to their short path length and large linear energy transfer. The
range of an alpha particle is three to six cell lengths and only one cell traversal is needed to cause
irreparable damage. Ideally the drug will bind to the targeted cells without causing damage to
surrounding healthy cells.
The use of radiation to treat cancer is well established and has been a strategy for over
100 years. During this time, external beam therapy has become the most common form of
radiation therapy. Advances in geometrical tumor targeting, treatment planning, optimization,
dose calculation, delivery, guidance, verification, and disease control have made external beam
therapy the standard delivery of therapeutic radiation. For a modern external beam radiation
treatment, the radiation therapy team may spend weeks designing and tailoring the optimal plan
by choosing variations in beam type, energy, treatment time, and geometry. Radionuclide
therapy has been a cancer treatment approach since the 1940’s with the use of 131I for the

1

treatment of thyroid disease. However, patient specific treatment design and workflow
innovation has severely lagged behind the advancements made in external beam therapy. In
radionuclide therapy it is common to prescribe fixed-dose non-specific administrations to all
patients. This leads to “consciously choosing that patients be treated with a lower standard of
care than external beam patients1.” These fixed administrations are based on calculations
performed on a stylized fixed geometry model of a standard human. Since radionuclide therapies
are systemic, toxicities are not only a function of administration but also functional and
anatomical variations.
With the growing interest in developing new radiopharmaceuticals that target specific
cells which previously could not be optimally treated, the field has made progress in entering the
era of personalized medicine. Developments in modeling biological endpoints and
pharmacokinetic analysis have led to the emergence of patient specific internal dosimetry.
Improvements in quantitative imaging and computational power have led to work in modeling an
individual patient’s anatomy and physiology and computing the 3D radiation dose distribution
specific to each patient using Monte Carlo.

1.2 Objectives
In this work, a novel targeted alpha therapy is developed and tested. The principal goal is
to develop a methodology for 3-dimensional patient specific internal radiation dosimetry for the
targeted alpha therapy that can be implemented clinically. The methodology should be quick,
straight forward and accurate. The workflow is initially developed using phantom studies and
then it is applied to a mouse experiment. Patient specific models are created using computed
tomography (CT) and spatial and temporal activity distribution maps are created using single

2

photon emission tomography (SPECT). Dosimetric calculations are performed using the Monte
Carlo N-Particle (MCNP) package. As a benchmark, the results of the dosimetric workflow will
be compared to conventional internal dosimetry methods.

1.3 Outline
This work is structured into six chapters. Chapter 2 starts by describing the radiation
biology and mechanism of action of alpha particles. The chapter continues with a summary of
the clinically relevant alpha emitting radionuclides. The final portion of this chapter is a
summary of internal radiation dosimetry methods.
Chapter 3 describes the identification of an issue that is commonly overlooked in targeted
alpha therapy development. Many alpha emitting radionuclides have complex decay chains
consisting of alpha emitting daughters. The radioactivity of these daughters must be quantified
for a complete analysis of the therapy. If the daughter species emit gamma rays, a scintillation
detector can be used and spectrum analysis can be performed to separate the daughter activities.
Scintillation detectors however suffer physical limitations with increasing activity. Therefore a
method is described that corrects the scintillation detector’s readings at higher activities using
Monte Carlo to permit the analysis of daughter products.
Chapter 4 describes the preclinical testing of the novel metastatic uveal melanoma
targeted alpha therapy. The chemistry, biology, and physics considerations are presented. The
physics portion includes the description of the indirect measurement of alpha activity for
administration analysis, blood pharmacokinetics, biodistribution, and conventional radiation
dosimetry.
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Chapter 5 describes the development of a multi-compartment pharmacokinetic model for
the targeted alpha therapy and a derivative that was developed and tested. The model can be used
to implement patient specific therapy by optimizing administration activities from simulated
biodistribution obtained from imaging and/or blood and urine samples.
Chapter 6 describes the development of the voxel-based 3D internal dosimetry
methodology. A companion imaging agent to the targeted alpha therapy is developed and tested.
Phantom studies are conducted to develop the image-to-Monte Carlo conversion algorithms. 3D
absorbed dose is generated for both the imaging agent and the therapeutic agent in mice and
validated by comparing to conventional methods
Chapter 7 summarizes the results of previous chapters.
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CHAPTER TWO:
BACKGROUND

2.1 Mechanism of Action
Since the discovery of radioactive materials, the effect of radiation on the properties of
matter has been of significant interest in the disciplines of material science, geology and
astrophysics. For example the first large-scale effect of radiation on solid material was observed
by E.P. Wigner from exposure to a nuclear fission reactor and was thus named the Wigner effect,
or "Wigner’s disease".2 Since then, the large spread of medical technology involving sources of
ionization radiation 3 and the development of nuclear weapons have caused a spike in studies of
the effect of radiation on living tissue. That work increased our understanding of the concept of
radiation risk and created new fields of scientific study, for example, radiation health safety,
radiation dosimetry, and radiation oncology.
Because of the high energy of alpha particles and stochastic nature of ionization
radiation, their effects may be observed on all levels of a biological system. Any molecule, cell,
tissue or organ can display alpha decay radiation damage and such damage can be localized, or
occur throughout the entire body of any multicellular organism.4
The first step in producing radiation effects is the generation of a primary recoil atom and
alpha particles by a radioactive decay. Such events take place very rapidly in much less than 1fs.5
In the case of alpha decay of radiopharmaceutical isotopes of interest, the average kinetic energy
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per recoil atom is ~100 keV, and the average kinetic energy deposited within the range of a
single alpha particle is on the order of 5 MeV. It is clear that the relatively high levels of energy
deposited by the combination of the fast moving heavy ions and high energy alpha particles can
cause large amounts of damage to solid matter. There are many methods to estimate the effect of
radiation in solid materials, i.e. the stopping power theory based on Coulombic interactions,
molecular dynamics, transport theory, etc. However, unlike solid materials, biological tissues do
not consist of solid crystalline structures, and this significantly increases the complexity of
estimating the effects of alpha decay (as well as other ionization radiations), making the
application of the aforementioned methods impossible or extremely difficult numerically. To
overcome such limitations, a semi-quantitative approach has been applied. First, the biological
effects observed in irradiated subjects were separated into one of two categories4,6: Deterministic
effects, which have a practical threshold absorption dose below which effects are negligible or
not evident; and stochastic effects, where the relationship between dosage and severity of effect
is either less evident or absent.
Maintaining the integrity of many different types of macromolecular structures is
important to cell viability and all cellular organic molecules are subject to damage by ionizing
radiation. However, the genomic DNA molecules are considered to be the most critical target for
the biological effects of ionizing radiation because intact DNA is required for cellular
replication, and damaged but improperly repaired DNA can result in fixation of genetic
mutations that can affect normal cellular function and viability.7 Ionizing radiation interacts with
DNA either by directly transferring energy to the biological material or indirectly by creating
reactive free radicals from the radiolysis of water. These interactions result in damage to the
DNA structure as a result of broken covalent bonds. Linear energy transfer (LET) is an approach
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to describe the spatial distribution of ionization and excitation produced by direct or indirect
effects of different types of radiation along a linear path.8 Alpha particles are high LET radiation
because they create dense ionizations and excitations in matter due to coulombic interactions
with atoms. Being a heavy charged particle, an alpha particle will continuously slow down along
its track with minimal deflection. Through the process of slowing down, the interaction crosssection towards the end of travel increases, resulting in increased LET, which is known as the
Bragg Peak.9,10
Relative biological effectiveness (RBE) is the ratio of the dose of a reference radiation
and the dose of a test radiation that produces the same biological effect. Some of the most
common biological effect measurements are necrotic and apoptotic (programmed) cell death,
DNA damage, chromosomal aberrations and genetic mutations. The RBE of alpha particles can
range from 3.5 to 4 for cell killing, 6 to 12 for mutation, and 10 for cell transformation.8 As a
comparison, the RBE for low LET electrons and photons is 1.
An important biological endpoint is cell killing. Damage to cells can be classified as
either sub-lethal events or lethal events. Sub-lethal events are due to the accumulation of damage
that has potential to be repaired, typically as a result of exposure to lower doses, and lethal
events typically result from irreparable damage due to exposure to higher doses.4 The ability to
repair these events is seen as a shoulder on the cell survival curve and is characteristic of low
LET radiation (Figure 1).11 A single event of high LET radiation can be lethal. The cell survival
curve for a lethal event does not have a shoulder, indicating the inability to repair.12
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Figure 1. Survival of a human kidney T-cell culture irradiated with ionizing particles of
different kinds: 1) particles with E= 2.5 MeV, LET=165 keV/m; 2) particles with E=25 MeV,
LET=25 keV/m; 3) deuterons with E=3.0 MeV, LET=20keV/m; 4) X-rays with E=20 keV
and LET=6 keV/m; 5) X-rays with E=250 keV and LET=2.5 keV/m; and 6) particles with
E=2.2 MeV, LET=0.3 keV/m. This figure and legend were reproduced from Kudryashow,
Y.B., Radiation Biophysics (Ionization Radiation). Nova Science Publishers Inc., 2006.
The DNA double strand break is the most biologically significant type of damage, which
occurs as a result of two single strand breaks in close proximity or a rupture of the double strand
at the site of interaction.13 Cell survival is highly dependent on the spatial distribution of double
strand breaks.8 Given the same dose, high LET radiation can create up to four times more double
strand breaks than low LET radiation. Also, the formation of high LET double strand breaks are
more complex compared to low LET in that they are less randomly distributed and form
clustered DNA damage to multiple base-pairs.9 It has been widely accepted that high oxygen
levels play a large role in a cell’s sensitivity to ionizing radiation and, hence, tumor hypoxia is an
established factor in resistance to radiation therapy.14 This is due to enhancement of free radical
production by the presence of oxygen. Free radical production occurs as a result of indirect
action, or low LET interactions. Since alpha particles interact directly with the DNA, the level of
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oxygen becomes irrelevant, hence, eliminating a major mechanism of resistance to therapy.4 See
Figure 1.
After exposure to radiation that results in DNA damage, the cell cycle can be stopped at
cell-cycle checkpoints which allow the cell to repair the damage via multiple repair mechanisms
in order to preserve genomic integrity.13 In the case of irreparable damage, the cell will
eventually undergo cell-death by apoptosis or necrosis. The two main repair mechanisms of
double strand breaks are homologous recombination and non-homologous end joining.
Homologous recombination occurs in the late S and G2 phases of DNA synthesis where an intact
DNA template is available, resulting in a more efficient and high fidelity repair. Nonhomologous end joining occurs throughout the cell cycle but is the only means of repair in G1
and early S phase. In this error prone repair method, DNA ends are rejoined with no sister
template.12 In this case chromosomal aberrations can occur as a result of recombining incorrect
DNA ends, i.e. combining a loose end to some other molecule, and truncation of ends. If
incorrect repair occurs prior to DNA replication, these errors can be replicated in daughter DNA
which can lead to mitotic cell death or can lead to the generation of genomic mutations without
cell death.12 There is also the situation where double strand breaks are not repaired and the
dividing cell enters mitosis, leading to mitotic catastrophe and eventual cell death. A higher
proportion of double strand breaks remain un-rejoined after exposure to high LET radiation.8
When it comes to damage from high LET alpha particles in close proximity to the cells being
irradiated, the main radiobiological effect is complex and irreparable DNA damage resulting in
cell death by either apoptosis or necrosis.
In the last few years, successful attempts have been made to explain the bystander
effect.14,15 The bystander effect is defined as effects that are observed in cells that have not been
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directly irradiated following the irradiation of other nearby cells. Two mechanisms were
proposed, one is the transfer of genomic instability through p53-mediated pathways and the other
suggests that irradiated cells secrete cytokines or other factors that transit to other cells that were
not irradiated and signal increased levels of intracellular reactive oxygen species.16 One of the
defined sub-classes of bystander effect is the “abscopal effect,” in which radiation treatment of a
tumor propagates to tumors outside the irradiated volume.16

A more recent publication

demonstrated an effect that might explain the abscopal experience.17 It was demonstrated that
alpha-particle treatment of prostate cancer cells generated an adaptive antitumoral immune
response, as has been previously reported for other forms of radiation. The combination of
bystander effects and the abscopal (likely immune) response in vivo are potential mechanisms of
efficacy for tumors that are not avid for the targeted α-emitter radiotherapy in a patient with
heterogeneous target expression.

2.2 Alpha Emitting Radionuclides
Using radiation as a method of cancer therapy requires delivering the maximum dose to
the tumor while minimizing dose to healthy tissues. Targeted radionuclide therapy is
advantageous in that it seeks molecular and functional targets within patient tumor sites. 18 Beta
emitting radionuclides (90Y,

131

I,

177

Lu,

186

Re) are used for cancer-targeted therapy but have

problems with cross fire irradiation of normal tissues due to their relatively long range in tissue
which is in the range of 0.5-12 mm. In contrast, alpha particles deposit higher energy over a
much shorter range (40-90 µm), potentially causing higher cytotoxicity to tumor cells while
delivering a lower dose to normal adjacent tissues.19Alpha emission is the process by which an
unstable nucleus ejects a highly energetic heavy charged particle consisting of two protons and
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two neutrons. Alpha particles have a higher LET (100keV/µm) compared to beta particles
(0.2keV/ µm) which results in dense ionization along its track in matter. The short range of alpha
emission provides specificity to the target cell population with minimal effect on surrounding
normal cells, and the high LET leads to a high frequency of irreparable DNA double strand
breaks.7 This limits cytotoxic effects to within a small distance from the location of decay. It has
been estimated that only one cell traversal by an alpha particle track is necessary to kill the cell
while thousands of beta traversals are required for the same effect.20 Because of the long range of
beta particles and the need of a high number of hits for cell killing, a large portion of the dose
deposited is outside of the intended target. Hence, beta-emitting radionuclides are typically used
for targeted treatment of non-solid or circulating types of cancer, i.e. leukemias and lymphomas,
where target cells are not stationary in order to minimize damage to surrounding normal tissues.
Regardless, use of alpha particles for targeted treatment of circulating disease could be an
improvement due to potentially reduced damage to normal tissues. Use of targeted alpha particle
therapy has been considered for killing isolated cancer cells in transit in the vascular and
lymphatic systems, in regressing tumors by disruption of tumor capillary networks and in
treatment of micrometastatic foci.21 In particular, targeted alpha particle therapy may be ideal for
treatment of solid metastases as the short range will primarily kill tumor cells with little
deleterious impact on surrounding normal tissue. Additionally, heterogeneity of target expression
has been observed within a given tumor or metastasis22 and this is thought to be a mechanism of
developing resistance to targeted therapies, where non-target expressing cells survive treatment
and clonally expand into a resistant population. In this case, alpha emissions from a targeted cell
will serve to kill surrounding untargeted cells within the effective range, potentially reducing the
development of resistance.
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A number of factors need to be considered in choosing an alpha emitting radionuclide for
therapy. These include proper nuclear characteristics, ease of radiochemical incorporation,
specific activity, synthesis yields, chemical and biological stability, availability, and cost.19
The physical half-life of the radionuclide should be long enough to allow for
radiosynthesis preparation and be compatible with the pharmacokinetics of tumor localization.23
The decay pathway of the alpha emitter should be carefully analyzed. Due to the conservation of
energy and linear momentum a daughter nuclide which subsequently decays by alpha emission
could detach from the radioimmunoconjugate, see for example.24 These free products could
travel away and deposit dose to healthy tissue. A decay chain that is long and complicated,
having many different decay types could also present an issue dosimetrically especially if the
daughter products are metabolized differently than the parent. A possible way to overcome this
issue is to use

225

Ac as an in vivo generator in which the delivery system is designed to be

internalized into the target cell where the toxic daughter elements may detach from the targeting
vector but remain trapped in the cell.25
Another important nuclear characteristic is having a large number of alpha emissions per
decay. The radiotoxicity associated with having multiple emissions could be high enough to kill
a tumor cell in a single decay. An accompanying gamma photon emission with energy suitable
for in vivo imaging is also beneficial to assist with pharmacokinetic and dosimetric evaluation.23
Another important element for radionuclide selection is availability. Alpha emitters are
produced either in cyclotron bombardment or by reactor irradiations, incorporated into a
generator, and eluted from a parental source. Obtaining radionuclides in pure form with high
specific activity and large quantities is essential for adequate therapeutic evaluation. High
specific activity is important to avoid receptor saturation by the unlabeled targeting agent.26 If
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membrane antigenic density is low, insufficient binding to tumor cells will occur.26
Transportation of these radionuclides safely and economically is also a key issue in selection.
While there are over 100 alpha emitting radionuclides, only several have been
investigated in preclinical and clinical studies. This is mostly due to radionuclides lacking
nuclear properties, the absence of viable chemistry, complicated decay chains, and production
and economic issues.27 Therefore radionuclides meeting the criteria for therapeutic use have been
limited to

225

Ac,

212

Bi,

213

Bi,

211

At,

212

Pb,

223

Ra, and

227

Th. The physical characteristics of these

isotopes can be seen in Table 1.

Table 1. Physical characteristics of alpha emitting radioisotopes investigated for clinical use.
Isotope
225

Ac
At
212
Bi
213
Bi
212
Pb
223
Ra
227
Th
211

Half-Life
10.1 d
7.2 h
1.01 h
45.6 min
10.6 h
11.4 d
18.7 d

Max Energy
(MeV)
5.83
5.87
6.09
5.87
6.09
5.87
6.04

Emissions Per
Decay
4 α, 2β1 α, 1 EC
1 α, 1β1 α, 2β1 α, 2β4 α, 2β5 α, 2β-

The first alpha emitter to be used in human clinical trials for therapy was
when it was labeled to the anti-leukemia antibody HuM195.28
generator based

225

213

213

Bi in 1997,

Bi is available through

Ac and decays with a 45.6 min half-life by emission of 1 alpha (8.37MeV)

and 2 betas. The generator is produced at Oak Ridge National Laboratory in the US and at the
Institute for Transuranium Elements in Karlsruhe Europe. In the decay of
emission of a 440keV isomeric gamma which is beneficial for imaging studies.
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213

Bi, there is an

211

At decays with a half-life of 7.2 h and emits 2 alphas through a split decay pathway

with energies of 5.87 and 7.45MeV. One path is to 207Bi by alpha emission followed by electron
capture to 207Pb and the other is by electron capture to 211Po followed by alpha emission to 207Pb.
An advantage of this decay path is that

211

Po emits 77-92keV characteristic x-rays which can be

used for imaging.27 The main disadvantages are availability and purity. Conventionally the
production of 211At requires an alpha particle cyclotron, which there are only a few worldwide, to
209

produce the

Bi(alpha,2n)211At reaction with minimal

210

At contamination.29 Astatine has

significant metallic characteristics that lead to complications in standard antibody labeling and
results in rapid release of free

211

At.27,30,31 To resolve this problem, approaches have been

developed in several research groups based on small linker molecules that create an aryl carbon–
astatine bond involving an astatodemetallation reaction using tin, silicon, or mercury
precursors.32
225

Ac is a radiometal with a half-life of 10.1 days and produces six radionuclide

daughters in the decay path to stable 209Bi. For each decay event of 225Ac, there are successively
four alpha and two beta emissions with high energy (alpha 8.38MeV, beta 1.42MeV). In the
decay of

225

Ac and its daughters there are several isomeric gamma emissions with energy

suitable for imaging studies. The relatively long half-life allows for a centralized production site
that can ship

225

Ac to users.33 The main method for generating

through the decay of
sources of

229

229

Th which originates from

233

225

Ac for clinical studies is

U. In the world there are the three main

Th: Oak Ridge National Laboratory (USA), The Institute of Physics and Power

Engineering (Russia), and The Institute for Transuranium Elements (Germany). The quantities
produced are not enough for global application of
for

225

225

Ac. To keep up with the increasing demand

Ac for clinical applications, it has been found that large scale quantities can be produced
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through high energy proton irradiation of

232

Th.34,35 To address the shortage the US Department

of Energy formed a Tri-lab collaboration of Los Alamos (LANL), Brookhaven (BNL) and Oak
Ridge (ORNL) National Laboratories with the goal of developing an alternative route for
production of Ac.36 Another limitation for this radionuclide has been with the radiochemical
stability of the attachment to immunoconjugate. McDevitt et al.25 state that instability of these
attachments is due to the high classical recoil energy (100-200keV) of the daughter product
which breaks the molecular bonds of the chelator. Significant advances have been made in
developing chelators that form thermodynamically stable and kinetically inert complexes with
225

Ac. Khabibullin et al., recently calculated the chelation stability of 225Ac and daughters in the

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator.37
As one potentially abundant starting material,
from

228

Th and decays via a branched pathway to

decay to stable

208

Pb.23 However,

212

208

212

Bi (1.01 h half-life) can be obtained

Tl (36% α) and

212

Po (64% β), then both

Bi has several disadvantages that potentially limit its use.

First, its short half-life can be problematic if the production and shipping processes are lengthy.
This issue can be solved by using

224

Ra as a generator to locally produce

212

Bi. Another

complication is the high energy gamma emission (2.6 MeV) which requires a considerable
amount of shielding to minimize exposure. This along with the short half-life makes shipping
difficult, resulting in an availability problem.
223

Ra is found naturally in trace amounts following the decay of

235

U, but it is mainly

produced artificially by the decay of 227Th (T1/2 = 18.7 days), which is produced from 227Ac (T1/2
= 21.77 years). Since

227

Ac is found only in traces in uranium and thorium ores, it is mainly

synthesized by 226Ra (T1/2=1600 years) irradiation in a nuclear reactor.38

223

Ra has a half-life of

11.4 days and emits 4 alpha particles, 2 beta particles and gamma rays on the path to stable
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207

Pb.24 While the emission of 4 alpha particles is advantageous for tumor toxicity,

219

Rn in

gaseous form is also emitted which can redistribute in the body and dose non-targeted cells.
The major challenge using

223

Ra is finding a suitable ligand for in vivo sequestration of

radium. 223Ra has cationic charge similar to Ca++ and because of this it is readily taken into bone.
Because of this characteristic,223Ra-dichlorde (Xofigo®) has demonstrated significant efficacy in
the palliative treatment of bone metastases in castration resistant prostate cancer and has FDA
approval for use in this application.24 However, this same property raises concerns about toxicity
to normal bone if used for targeting cancer cells not associated with bone.
227

223

Th can be produced continuously from 227Ac and decays with a half-life of 18.7 days to

Ra39. The long half-life is beneficial for radiolabeling and targeting.

227

Th also decays with

accompanying gamma emissions of 236keV and 50keV which can be used for imaging but are
low enough to avoid the need for patient shielding.
212

Pb has a 10.6 h half -life and is produced either from the decay chain of 228Th or by the

224

Ra generator.29 Because of its long half-life and the fact that 212Pb is a β emitter that decays to

212

Bi, one approach has been to use this radionuclide as an in vivo generator to compensate for

the short half-life of

212

Bi.40 212Pb can deliver over ten times the dose per unit of administered

activity compared to 212Bi or 213Bi.41 The major issue with 212Pb is the electron capture and auger
electron emissions which can cause significant recoil of the

212

Bi daughter.42 The free

212

Pb has

been shown to cause severe bone marrow toxicity 43 while the free Bi has shown to cause kidney
toxicity. By co-injecting DTPA or EDTA chelating agents, rapid release of free
achieved.44
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212

Bi can be

2.3 Internal Radiation Dosimetry
Dosimetry provides a means for evaluating the efficacy of a radiation therapy modality.4
Because the goal is to deliver high dose to tumor cells with minimal dose to normal tissues, it is
of great importance to quantify accurately where, when, and how dose is being deposited. The
absorbed dose assessment involves the calculation of the total energy per unit mass of the
volume of interest.45 These volumes can be whole organs, tissue subregions, voxelized tissue
structures, or individual cellular compartments.46 Internal radiation dosimetry requires the
knowledge the radionuclide’s physical properties (i.e. type of particles, emission energies,
abundances, half-lives) and the measurements of biological properties (i.e. uptake, clearance, and
tissue masses). Internal dosimetry can be divided into two categories: fixed-geometry and 3D
image based dosimetry.
The conventional method of internal dosimetry was developed by the Medical Internal
Radiation Dose Committee (MIRD) in the 1960’s. The MIRD method falls into the fixed
geometry category. In this method, the dose calculation is dependent on the amount of activity as
a function of time in a source organ, the energy emitted per disintegration and the fraction of
emitted energy absorbed by a target organ.47 The fraction of energy absorbed from a source
organ to a target organ for a given radionuclide is derived from a fixed geometry using a
standard anatomical model.
The fundamental equation for calculating absorbed dose using the MIRD schema is given in
Equation 1.
𝑥

𝑥

∑ ∆ 𝜑(𝑟 ←𝑟 ;𝐸 )
𝐷𝑥 (𝑟𝑇 , 𝑇𝐷 ) = 𝐴̃(𝑟𝑆 , 𝑇𝐷 ) 𝑖 𝑖 𝑀(𝑟𝑇 ) 𝑆 𝑖
𝑇

(1)

where 𝐴̃(𝑟𝑆 , 𝑇𝐷 ) is the total number of nuclear transitions in the target region, ∆𝑖𝑥 is the mean
energy emitted per disintegration for the ith emission of type x, 𝜑(𝑟𝑇 ← 𝑟𝑆 ; 𝐸𝑖𝑥 ) is the fraction of
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energy emitted per nuclear transition in the source region that is absorbed in the target region by
the ith emission of type x that is emitted with initial energy E, and 𝑀(𝑟𝑇 ) is the mass of the target
region. 𝐴̃(𝑟𝑆 , 𝑇𝐷 ), known as the cumulated activity, describes the kinetic portion of the dose and
depends on the spatial and temporal distribution of the radionuclide. Serial activity
measurements are taken over time post-administration and a time activity curve (TAC) is
generated. The TAC is then fitted with a kinetic compartmental model and integrated over time
to determine the total number of disintegrations in the source organ:
𝑇
𝐴̃(𝑟𝑆 , 𝑇𝐷 ) = ∫0 𝐷 𝐴𝑠 (𝑡)𝑑𝑡

(2)

The mean energy emitted per emission ∆𝑖 is a physical property of the radionuclide and
can be obtained from nuclear decay tables. The absorbed fraction for each decay type, 𝜑, is
dependent on the reference phantom fixed geometry and obtained through Monte Carlo
calculations. One can define an “S” value as:
𝑆=

𝑥
∑𝑖 ∆𝑥
𝑖 𝜑(𝑟𝑇 ←𝑟𝑆 ;𝐸𝑖 )

𝑀(𝑟𝑇 )

(3)

Reducing Equation 1 to:
𝐷𝑥 (𝑟𝑇 , 𝑇𝐷 ) = ∑𝑟𝑠 𝐴̃(𝑟𝑆 , 𝑇𝐷 ) × 𝑆

(4)

The S value is pre-calculated and tabulated from the fixed geometry and tabulated for each
particular radionuclide.
The value of the MIRD schema is its simplicity in that the physical aspects of the dose
calculation are separated and all that needs to be obtained experimentally is the temporal kinetic
information. The disadvantages of this method are in the broad assumptions that are made. This
conventional method for the calculation of mean absorbed dose assumes uniform activity within
the source volumes as well as assuming that the result will be predictive of biological effects.
The spatial distribution of activity cannot be determined. The anatomical model is based on a
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very primitive mathematical geometry consisting uniform density shapes. The most extensive
software that has adapted the MIRD S factors is OLINDA/EXM which has calculated internal
dose for over 200 radionuclides, including alpha emitters, in 10 different phantoms.48 The
predetermined S values from these phantoms are unrealistic for human application. As a result of
these assumptions it has been estimated that errors range from 30-100%.49 In therapeutic
applications, where tumor control probability and normal tissue toxicity are of utmost
importance, this standardized fixed geometry is unacceptable. In radionuclide therapy, especially
alpha therapy, nonuniform activity distributions arise over temporal and spatial dimensions.
Using the mean absorbed dose will under- or- over estimate subregions in the volume of interest.
The outcome of a therapy is then limited by the normal tissue toxicity.50
With the development of high quality 3-dimensional imaging capabilities and increasing
computational power, patient specific internal dosimetry has become possible. Using 3D
computed tomography (CT) images, a phantom specific to the patient’s anatomy can be
generated. Accurate organ volumes, location and densities are obtained through CT imaging.
These voxelized volumes are segmented into regions of interest (ROI’s) to define source and
target regions. Functional imaging such as single photon computed tomography (SPECT) or
positron emission tomography (PET) is then used to obtain spatial and temporal biodistribution,
at the voxel level, in the ROI’s. The SPECT/CT images are registered together and integrated
voxel by voxel over time to obtain the 3D time integrated activity. A Monte Carlo package is
then employed to model particle transport and energy deposition in each voxel.
Three methods of 3D voxel-based dosimetry using Monte Carlo can be used: (1) the
voxel S value method, (2) the point dose kernel convolution method, and (3) full direct Monte
Carlo calculation
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The fastest is the voxel S value method. This method extends on the original MIRD
schema by developing voxelized phantoms to better match standard human anatomy. For
example, Christy and Eckerman developed phantoms that represented a male, a female, and
children.51 Later, as computational power increased, voxelized phantoms like VoxelMan were
created based off of 3D imaging.52 MIRD Pamphlet No. 17 describes a method to extend the S
value formalism to the voxel level to account for nonuniform distributions of activity.53 While
accuracy is improved, the voxel S value method is still a model based approach to dosimetry.
In the point dose kernel convolution method, Monte Carlo is used to generate
radionuclide specific absorbed dose per decay maps at radial distances from an isotropic point
source in a homogeneous medium. The patient specific activity distribution obtained from
SPECT imaging is then convolved with the dose kernel to obtain a 3D dose distribution. The
major disadvantage of this method is that since the dose kernels are obtained in homogeneous
media, tissue heterogeneity is not modeled.
The most accurate method for calculating 3D internal absorbed dose at the voxel level is
direct Monte Carlo calculation. With full Monte Carlo simulation, all emission types can be
simulated, tracked, and tallied to generate 3D dose distributions specific to the patient’s anatomy
accounting for tissue heterogeneity. The patient’s CT dataset is converted into a voxelized
phantom. Each voxel is defined to have a specific elemental composition and density creating an
attenuation map. The patient’s SPECT provides the voxelized activity distribution map for the
Monte Carlo source definition. Full Monte Carlo simulations are performed and energy
deposition is tallied in every voxel within the patient derived phantom. Several software
packages are available for 3D patient specific dosimetry including MCID 54, OEDIPE 55, and
SCMS 56 which are based on MCNP, 3D-RD 57 and DOSIMG 58 which are based on EGS 59,
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RAYDOSE 60 and RAPID 61 which are based on GEANT4 62, and DPM 63 which is not a public
domain code. Both MCNP and GEANT4 can simulate alpha particles while EGS can only
transport photons and electrons. While direct Monte Carlo methods are the most accurate means
to perform 3D image based internal dosimetry, their use in the clinic has been limited due to
complexity and expensive computational requirements.
While many radionuclides in radiopharmaceutical therapy have accompanying photon
emissions, the energies and abundances are not large enough for practical 3D biodistribution
studies using SPECT or PET. To overcome this obstacle, companion imaging agents have been
developed. This theranostic approach involves developing a SPECT or PET tracer compound
that will have similar biodistribution and pharmacokinetics as the therapeutic. For optimized
treatment planning, the imaging agent is administered, the 3D accumulated activity distribution
is obtained, and one of the above Monte Carlo approaches is employed to calculate what the
absorbed dose will be in organs of interest following administration of the therapeutic agent.
This approach has been used for pretreatment dosimetric analysis for many
radiopharmaceuticals. Examples of using the theranostic approach include using 123I/ 131I metaiodobenzylguanidine (mIBG) in neuroblastomas, pheochromocytomas, and
paragangliomas64, 99mTc/ 188Re-hydroxyethylidene diphosphate (HEDP) for osteoblastic bone
metastases65, 68Ga/177Lu-DOTA-TATE for peptide receptor radionuclide therapy of metastatic
neuroendocrine neaoplasia66, 18F/131I-F-ICF15002 for metastatic melanoma67, and 111In/90Yibritumomab tiuxetan for B-cell non-Hodgkin’s lymphoma68. For image based dosimetry of the
223

Ra-dichloide alpha emitting radiopharmaceutical, 99mTc-methyl diphosphonate has shown to

be a suitable companion imaging agent in the treatment of treatment of bone metastases69. The
68

Ga/225Ac-Prostate-specific membrane antigen-617 (PSMA-617) 70 and the 203Pb/212Pb-DOTA-
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MC1L71 pairs have also been used in dose calculations for the targeted alpha therapy of
metastatic castration resistant prostate cancer and metastatic melanoma respectively.
The use of companion imaging agents for dose calculations improves on conventional
methods. However, in most cases, the kinetic data obtained from the images are input into
OLINDA and only mean organ doses are reported. For optimized treatment planning, the
dosimetry calculations need to be performed at the voxel level. In this work I will expand on the
conventional method of internal dose calculation used by OLINDA by developing a
methodology using a companion imaging agent to calculate absorbed dose at the voxel level for
our targeted alpha therapy.
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CHAPTER THREE:
A MONTE CARLO METHOD FOR DETERMINING THE RESPONSE
RELATIONSHIP BETWEEN TWO COMMONLY USED DETECTORS TO
INDIRECTLY MEASURE ALPHA RADIATION

Note to Reader
This research was originally published in Molecules. A Monte Carlo Method for Determining the
Response Relationship between Two Commonly Used Detectors to Indirectly Measure Alpha
Particle Radiation Activity. Christopher J. Tichacek, Mikalai Budzevich, Thaddeus J. Wadas,
David L. Morse, Eduardo G. Moros. Molecules 2019, 24(18), 3397.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.

3.1 Introduction
The use of targeted ligands to deliver alpha particles directly to cancer cells has become a
promising strategy to treat tumors.70,72-74 This is because of their short path length of 40–80 µm
and high linear energy transfer (LET~100 keV/µm).75 These two properties make alpha particles
highly cytotoxic to targeted cells, with little damage to surrounding normal cells.
Owing to the large amount of energy deposited by alpha particles, it is important to quantify
the radioactivity of the targeted radiopharmaceutical initially injected and its subsequent
biodistribution, pharmacokinetics, and radiation dose deposited in various tissues. As a result of
its short path length, the direct measurement of alpha particles’ activity in tissues is not possible
in most, if not all, preclinical scenarios. If a parent metastable radioisotope also emits gamma
rays, indirect methods of detection such as gamma spectroscopy can be used to estimate activity

23

using scintillation detectors and well-type ion chambers that are commonly available in research
laboratories and nuclear medicine clinics.
Actinium-225 (225Ac) was chosen as the radionuclide for alpha-particle therapy (TAT)
targeted to the melanocortin 1 receptor for treatment of metastatic uveal melanoma76, the
prostate-specific membrane antigen (PSMA) for metastatic prostate cancer72, and CD33 for acute
myeloid leukemia.77 Clinical studies have been carried out for the PSMA and CD33 TATs and
others in pre-clinical development will soon go to clinical trials.76
225

Ac has a 10-day half-life and decays via six daughter radionuclides resulting in a net of

four alpha particles per Actinium disintegration (Figure 2).20,78
221

225

Ac and two of its daughters,

Fr and 213Bi, also decay with accompanying isomeric gamma photons. Using gamma detection

systems, such as ion chambers or scintillation detectors, it is possible to indirectly determine the
alpha activity by gamma ray abundance per decay conversions.

Figure 2. Decay chain of Actinium-225 (225Ac).79

In the clinic, ion chambers are readily available and their use is the standard of practice for
checking activities for diagnostic and therapeutic agents. An ion chamber reading does not
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discriminate the collected charge between the parent and daughter radionuclides because it does
not provide energy identification. In these situations, gamma spectroscopy using scintillation or
semiconductor detectors, such as a sodium iodide doped with thallium scintillation detector
[NaI(Tl)] or a high purity germanium (HPGe) detector, can be used. With this approach, it is
possible to determine the activity of each gamma emitting daughter, which gives more
information on how the decay species behave.
While HPGe seems to be the attractive option owing to its superior energy resolution, its
performance suffers as a result of its low detection efficiency, cost, and requirement of
sophisticated cooling systems. Despite the advantages of the NaI(Tl), dead time losses at higher
activities and poor energy resolution may also provide incorrect activity measurements, leading
to underestimation or overestimation of radiation dose.80
In pre-clinical and clinical biodistribution studies, activity measurements of collected blood
and tissues are used to calculate pharmacokinetics and radiation dosimetry. Therefore, accurate
measurements for

225

Ac and daughters are needed. Hence, scintillation detector measurements

are needed to generate these spectra. Alpha radiation dosimetry is performed using the methods
recommended by the Committee on Medical Internal Radiation Dose.4,46 It is essential that these
measurements are accurate because the dosimetry estimates are then extrapolated to human
estimations and, therefore, serve as the fundamental basis for all patient safety measures.
Scintillation detectors are calibrated by analyzing three aspects of the detector: energy,
resolution, and efficiency.81 Once the detector is fully calibrated, it can be used to perform
gamma spectroscopic measurements in order to determine the activity of radioactive samples.8287

Ion chambers are calibrated by measuring a sample of the radiopharmaceutical in question

with known activity, correcting for decay, and applying a calibration factor. The American
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National Standards Institute (ANSI) recommends that the applied calibration factor adjusts the
measurement to within ±10% of the known activity.88 Although reference standards have been
developed for isotopes used in internal radiotherapy, for example,

177

Lu

89 225

Ac standards are

currently under development by NIST and are not yet available. For this study,

225

Ac provided

by Oak Ridge National Lab was used as a cross-reference source.
While there are evident limitations in making clinical predictions when translating a
radiopharmaceutical from mice to humans, it is important to minimize these limitations that are
the result of instrumentation. Herein, a threshold is identified above which the scintillation
detector cannot accurately measure the activities of

225

Ac and daughters. An activity response

relationship between the ion chamber and scintillation detector measurements is reported and
used in a method to improve activity determination above the threshold by correcting
scintillation detector measurements via Monte Carlo simulations. These corrections improve the
dosimetry of pre-clinical work and ultimately facilitate the translation of the new
radiopharmaceutical to the human clinic.

3.2 Materials and Methods
3.2.1

Mathematical Model

The 225Ac decay chain can be characterized by a system of ordinary differential equations that
describe the activities and abundances of each species as a function of time (Figure 3).90
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Figure 3. System of equations describing the decay of 225Ac to the very long-lived 209Bi.79

In Figure 3, 𝑁𝑥 and 𝜆𝑥 denote the number of atoms of radionuclide and the decay constant of
radionuclide X, respectively. These equations were simultaneously solved in Mathematica with the
initial (time zero)

225

Ac activity set to 3.7 x 104 kBq and all daughters’ activities set to 0 kBq to

determine the times at which daughter products reach equilibrium with the parent.

3.2.2

Monte Carlo Model

The Monte Carlo N-Particle version 6.1 (MCNP6.1) package was used to simulate the pulse
height gamma distribution from 225Ac.91 A computational model of the 2” × 2” NaI(Tl) 4π detector
was built using the material compositions and dimensions given in the manufacturer’s manual, as
illustrated in Figure 4.92
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Figure 4. Geometry of the Monte Carlo model wipe test scintillator detector. Image generated
using the Visual Editor software for MCNP. 2: NaI; 3: MgO; 4: Al; 6: polyethylene; 7: air; 8: H20
with 225Ac, 221Fr, 213Bi source distributions.79

A standard 5 mL polyethylene test tube filled with 1 mL of water was placed in the well of the
detector. The source was defined to be uniformly distributed in the 1 mL water volume. All 75
photon emissions from

225

Ac,

221

Fr, and

213

Bi were defined by energy and abundance.78 The

photomultiplier tube was modeled as a 30 mm diameter aluminum cylinder to account for
backscatter.93
Photon transport was conducted using the mcplib84 photoatomic data library and detailed
photon physics interactions.78 These include Thomson scattering, Compton scattering, and
photoelectric absorption with the creation of fluorescence photons or Auger electrons. Full photon
and electron simulations were performed and spectra were compared to those obtained from only
photon transport. Photon and electron cell importances were set to 1 for all cells in the geometry. A
mean percent difference of less than 1% between photon/electron transport and photon only
transport was observed in benchmark generated spectra of

137

Cs. There were also less than 1%

differences in the Compton edge and Compton regions. Therefore, the computationally expensive
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tracking of electrons was omitted in subsequent simulations and electron cell importances were set
to 0. In this case, the electrons generated are assumed to deposit their energy locally. Any electron
induced bremsstrahlung photons produced are accounted for in the thick-target bremsstrahlung
model.94 This model skips the electron tracking step and transports the generated photon in the
direction of the parent electron.
The pulse height distribution tally (F8) was used to calculate the deposited energy in the
NaI(Tl) crystal. This tally accumulates the kinetic energy lost by local photon-induced secondary
electrons, per history, in a specified volume. The tally was divided into 64 bins, each with a 12.5
keV width to match the energy resolution of the detector. To relate the simulated response to
activity, values for the number of gamma emissions per disintegration for each isotope, scaled by
the activity, were placed on the source probability card in the source definition. The resulting
tallies were then multiplied by the sum of these values, the live acquisition time, and an activity
conversion factor containing photon abundance per decay. For each simulation, 2 x 108 histories
were run to achieve less than 1% error under each photopeak.
MCNP6.1 models an ideal detector and thus does not take into account the Gaussian shape of
experimental NaI(Tl) energy resolution resulting from intrinsic light collection inefficiency,
statistical fluctuation in charge multiplication in the photomultiplier tube, and electronic noise.95
To account for the statistical variance of physical spectra, a Gaussian energy broadening function
(MCNP6.1 FT8 GEB) was applied to the simulated pulse height distribution. The GEB function
was obtained experimentally from measurements of the detector’s specific full width at half
maximum (FWHM) from a set of isotopes of differing energies. Spectra from five isotopes were
measured and the FWHM of each peak was calculated. The isotopes used and their physical
characteristics are listed in Table 2.
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Table 2. Physical characteristics of the radioactive sources used for NaI(Tl) detector energy
response measurements.78,79
Source
129
I
241
Am
57
Co
68
Ga
137
Cs

Half-Life
1.67 yr
432.6 yr
271.7 d
67.7 m
30.1 yr

Energy (keV)
39.5
59.5
122.0
511.0
661.6

A curve of FWHM as a function of energy was fit with the following nonlinear function
shown in Equation 591:
𝐹𝑊𝐻𝑀 = 𝑎 + 𝑏√𝐸 + 𝑐𝐸 2 ,

(5)

where E is the incident energy of the incident photon in keV; and a, b, and c are parameters that
were determined by least squares fitting and input in the FT8 command.

3.2.3

Monte Carlo Simulations

There are no standard NIST-traceable calibration sources for
model. Instead, the spectrum of a NIST-traceable 155.4 kBq

225

Ac to validate the detector

137

Cs (662 keV photopeak) source

was measured in the NaI(Tl) detector and compared to a simulated spectrum of the same activity
for validation.
After the model was validated, a high definition version of the F8 pulse height tally (1 keV bin
width) was simulated with only
definition simulations of

221

225

Ac defined as the source. This was followed by separate high

Fr and

213

Bi. These simulations were done to see what radiations

contribute to each peak, which are masked by the poor energy resolution of the NaI(Tl) detector.
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3.2.4 Experimental Measurements
The 225Ac used in this work was obtained from Oak Ridge National Laboratory (ORNL). The
AtomlabTM Wipe Test Counter (Biodex Medical Systems, Inc., Shirley, New York, USA) was
used to perform gamma spectroscopy measurements with 225Ac. The wipe test counter is a 2” × 2”
NaI(Tl) well-type scintillation detector with 1.2 cm of lead shielding. The multichannel analyzer
associated with the wipe test NaI(Tl) detector has 64 12.5 keV channels ranging from 0 to 800
keV. Spectra obtained with the NaI(Tl) detector for 30 s acquisition time and full energy window
to include gamma counts from 225Ac, with composite peak at 99.8 keV, and from its two gammaemitting daughters, 221Fr (T1/2 = 4.9 min) with a peak at 218.1 keV and 213Bi (T1/2 = 46 min) with a
peak at 440.5 keV. Background spectrum measurements were performed and subtracted from all
obtained 225Ac spectra. The net background readings for the NaI(Tl) detector were in the range of
100 to 200 net counts per minute. The net counts for an

225

Ac sample of 45 kBq activity was

444,000 per minute.
Dead time measurements and calculations were performed according to the two-source
method.80 Two different sources of 22Na with different activities were each measured individually
and then in combination.
In-house software was developed using MATLAB to calculate the net number of gamma
counts, N, by fitting each peak with a Gaussian fit and integrating. Alpha particle activity for each
species was calculated using factors for gamma abundance (Y) per alpha decay:

225

Ac (1%), 221Fr

(11.4%), 213Bi (25.9%).78
The detector efficiency, ε, and energy calibration for the NaI(Tl) detector were determined by
performing measurements of NIST-traceable

137

Cs,
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133

Ba, and

57

Co sources. These radionuclides

have numerous photopeaks covering the gamma energy spectrum of

225

Ac. The activity is then

given by the following Equation 6:
𝐴=

𝑁
,
𝑡∗𝜀∗𝑌

(6)

where t is live time. The activity of 225Ac determined using this approach was compared to a decay
corrected sample of known activity from ORNL. A factor of 0.082 was applied to Equation 2 to
obtain 225Ac activity values to within 5% of the ORNL specified 225Ac activity. The uncertainty in
the NaI(Tl)-determined activity was calculated by propagating individual uncertainties in the net
number of counts and the efficiency measurements, as is typically done in nuclear counting
measurements.
The AtomlabTM 500 Dose Calibrator is a well-type pressured ion chamber filled with argon
gas that is commonly used in the clinic. This instrument was calibrated for energy and efficiency
with the following NIST-traceable sources: 137Cs (6.63 MBq), 57Co (39.26 MBq), and 133Ba (5.71
MBq) by the vendor. Lower activity NIST-traceable sources provided by Eckert & Ziegler were
also used:

137

Cs with 158.73 kBq and 57Co with 391.09 kBq activities. No significant variation in

the calibration coefficient as a function of photon energy was observed. An ion chamber linearity
test was performed with 18F in the activity range of 1.2 GBq to 266.0 kBq and a variance of 1.4%
was observed. The dial number was set at 38.2 for 225Ac, as indicated by the vendor and confirmed
by our comparison with two decay corrected samples of different activities obtained from Oak
Ridge. Measurements of these samples in the ion chamber agreed with the Oak Ridge
measurements to within 7%. In order to determine the relationship between this ion chamber and
the NaI(Tl) detector, six different activities of

225

Ac samples were measured using the ion

chamber: 70.3 ± 7.0, 144.3 ± 14.4, 222.0 ± 22.2, 299.7 ± 30.0, 370.0 ± 37.0, and 447.7 ± 44.7 kBq.
Each sample was measured and placed in the NaI(Tl) detector, and a spectrum was obtained and
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compared. Using the activity reading from the ion chamber as the initial parent–daughter
equilibrium activity input for the Monte Carlo model, simulated spectra were calculated and
compared to the measured spectra from the NaI(Tl) detector. Mean absolute percent differences at
analogous bins between the experimental and simulated spectra were calculated. Using the ion
chamber measured activity as input to the Monte Carlo simulations underestimated the readings
from the NaI(Tl), so several successive runs were completed using different activities as input in
symmetrical range around the initial point in order to match the spectra. The percent differences
were plotted against input activity and fitted with a linear model. The x-intercept was found in
order to determine the minimum mean percent difference between the measured and simulated
spectra. This process was repeated for each sample and an activity response function relationship
was determined between the ion chamber and the NaI(Tl) detector. The uncertainty in the activity
relationship determined using this methodology was analyzed by adding the uncertainties in the
2
2
NaI(Tl) measurements, 𝜎𝑁𝑎𝐼
; the ion chamber measurements, 𝜎𝐼𝐶
; and the Monte Carlo
2
calculations, 𝜎𝑀𝐶
, in quadrature (Equation 7):
2
2
2
𝜎𝐴 = √𝜎𝑁𝑎𝐼
+ 𝜎𝐼𝐶
+ 𝜎𝑀𝐶
.

(7)

3.3 Results
The system of ordinary differential equations describing the 225Ac decay chain was solved to
determine the daughters’ activities as a function of time; these results are plotted in Figure 8 for
225

Ac,

221

Fr, and

equilibrium with

213

Bi. For an initial activity of 3.7 × 104 kBq of

225

Ac in 55 minutes, while

213

225

Ac,

221

Fr reaches secular

Bi takes 380 minutes. Therefore, after 380

minutes (6.37 h), the parent and all daughter nuclides are in secular equilibrium.
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Figure 5. Solutions to system of decay ordinary differential equations of for an initial activity of
3.7 × 104 kBq of 225Ac.79

To account for the statistical variance of physical spectra, a Gaussian energy broadening
function was integrated with the ideal Monte Carlo simulation model. The parameters of this
function were determined by nonlinear fitting of the measured FWHM versus energy. These
parameters were determined to be a = 0.005616, b = 0.0521, and c = 2.027 with an R-squared
value of 0.9984. This allowed the benchmark validation of the Monte Carlo model using the
137

Cs standard source (Figure 6). Simulating 155.4 kBq, the known source activity, showed a

1.02 mean percent difference at analogous bins between measured and simulated spectra.
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Figure 6. Comparison of measured and simulated spectra of 137Cs.79

The measured NaI(Tl) gamma spectrum and Gaussian peak fitting of 225Ac and its daughters
can be seen in Figure 10. The two source method was used to determine the dead time of the
scintillation detector to characterize the saturation of the signal with increasing activity. The
value was determined to be 4.6 × 10−5 s-1. The dead time value was incorporated into the gamma
spectrum fitting method that was used to determine the scintillation detector activities of
221

225

Ac,

Fr, and 213Bi, and these values were compared to the ion chamber measurements (Table 3). All

samples were in secular equilibrium during measurement, as shown in Figure 8. The ion chamber
manufacturer error is reported as 3%. Measurements using NIST-traceable sources within the
activity range of 5.705 to 39.257 MBq had 3% uncertainties. However, when measuring NISTtraceable sources at the lower activities of 158.73 and 391.09 kBq, the uncertainties were 9.7%
and 9.6%, respectively.
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Figure 7. NaI(Tl) measured gamma spectrum with Gaussian fitting.79
Table 3. Ion chamber and NaI(Tl) measured activities. Single measurements were taken in each
detector. Notice that as the ion chamber readings increase, the discrepancies with the NaI(Tl)
increase. All values in kBq. Note that the uncertainties in the ion chamber readings are expressed
as 10% in accordance with the calibration measurements in the activity range (above). The
NaI(Tl) uncertainties are expressed as the propagation of uncertainties in all steps of the
calculation. The difference between the ion chamber readings and the NaI(Tl) determined
activity for 225Ac are indicated in the last column to the right.79
NaI(Tl) Determined Activities
225

Ion Chamber Reading
70.3 ± 7.0
144.3 ± 14.4
222.0 ± 22.2
299.7 ± 30.0
370.0 ± 37.0
447.7 ± 44.7

225

221

Ac

57.35 ± 7.57
96.20 ± 9.81
124.69 ± 11.17
140.23 ± 11.84
152.07 ± 12.33
140.23 ± 11.84

Fr

66.97 ± 8.18
115.07 ± 10.73
152.81 ± 12.36
177.97 ± 13.34
198.32 ± 14.08
211.64 ± 14.55

213

Bi

63.64 ± 7.98
111.74 ± 10.57
143.93 ± 12.00
165.39 ± 12.86
182.41 ± 13.51
187.59 ± 13.70

Ac
Percent
Difference
20.23
40.00
56.14
72.50
83.49
104.59

The spectra acquired by the scintillation detector (Figure 8) have overlapping multiple peaks
that are further masked by the poor resolution of the detector. Monte Carlo simulations with 1
keV resolution were run for the parent and gamma emitting daughter radioisotopes. As observed
in Figure 5,

225

Ac,

221

Fr, and

213

Bi all exhibit many peaks in the 90 to 200 keV range. Monte
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Carlo simulations allowed for the accounting of contributions from each individual radioisotope
to the overlapping gamma spectra.

Figure 8. High definition Monte Carlo simulated gamma spectra of (A) 225Ac, (B) 221Fr,
(C) 213Bi, and (D) all three superimposed.79

Monte Carlo simulations were run using the bin width of the NaI(Tl) detector and ion
chamber readings. The resulting spectra were compared to the corresponding scintillation
detector spectra and it was observed that as the readings increased, the percent difference
between the measured and simulated spectra increased. The percent differences ranged from
19% at 70.3 kBq up to 156% at 447.7 kBq. This is illustrated in Figure 9. The readings that
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minimized the mean percent differences were used as the equilibrium input activities in the
Monte Carlo simulations. Figure 10 shows the matching of simulated spectra to measured spectra
for all six of the samples of different quantities. This procedure was repeated for all ion chamber
readings. Figure 11 shows the ion chamber reading and the simulated activity that matches to
within 1% of the NaI(Tl) spectra for all of the samples. At low readings, the measured and
simulated quantities agree reasonably well: 70.3 kBq measured in the ion chamber matched with
62.9 kBq equilibrium Monte Carlo activity and 144.3 kBq measured in the ion chamber matched
with 107.3 kBq Monte Carlo activity. For larger ion chamber readings, the matched response
began to plateau.

Figure 9. The mean percent difference between measured spectra and simulated spectra using the
ion chamber reading measurement as input for the Monte Carlo model.79
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Figure 10. Measured vs. simulated 225Ac spectra for (A) 70.3 kBq (0.17%), (B) 144.3 kBq
(0.5%), (C) 222.0 kBq (0.19%), (D) 299.7 kBq (0.99%), (E) 370.0 kBq (0.11%), and (F) 447.7
kBq (0.02%). The values in parentheses are the mean percent differences between the two
spectra.79
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Figure 11. Activity response relationship between ion chamber reading and Monte Carlo-NaI(Tl)
corrected spectra activity.79

3.4 Discussion
The purpose of this work is to develop a method to determine the activities of

225

Ac and

daughters in samples using standard clinical instruments. This is important for the determination
of blood clearance pharmacokinetics and tissue biodistribution, both of which are used for
radiation dosimetry calculations. In this work, an activity response relationship is determined
between two radiation detectors commonly used for pre-clinical and clinical applications, a welltype NaI(Tl) scintillation detector and an ion chamber, respectively, where

225

Ac activities

between the range of 70 to 450 kBq are not accurately measured by the scintillation detector.
This relationship was used to inform Monte Carlo simulations that corrected scintillation detector
measurements for accurate readings within this range. Although the error of the ion chamber
measurements increased to ~10% within this activity range, compared with errors of 3%
observed when measuring activities as low as 6 MBq, the error within this range for the
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scintillation detector as compared with the benchmarked Monte Carlo simulations ranged from
20% to 160% (Figure 9).
Several preclinical studies have reported using a NaI(Tl) gamma counter to measure

225

Ac

injection and biodistribution activities.25,96-99 Ion chambers are commonly used in nuclear
medicine departments to prepare radiopharmaceuticals for patient injection. Measuring the
activity of radioisotopes with complicated decay pathways, such as in the case of

225

Ac, the

readings are not only the result of the parent’s activity, but also from the contributions from the
daughters’ activities. From the solution of the system of decay equations, it was determined that
225

Ac and its daughters reached secular equilibrium in less than seven hours. While the daughters

emit alpha particles and/or beta particles, the ranges of these particles are not penetrative enough
to enter the ion chamber. Therefore, the ion chamber reading is a result of the gamma rays
emitted from

225

Ac,

221

Fr, and

injection activities for

225

213

Bi. For example, a recent human

225

Ac therapy study reported

Ac, but it was not clear if the reported values were from bulk

measurements or if spectra were acquired and only 225Ac emissions were considered.78
Several groups have built Monte Carlo models of NaI(Tl) detectors to simulate response
functions based on standard benchmark simulations and measurements of

137

Cs without

description of further extensions of their models.93,100-104 Herein, this procedure was extended to
include the detector response for

225

Ac and its daughters. Implementation of the adjustment

coefficients obtained by the nonlinear fitting into the Monte Carlo model adequately described
the Gaussian spread of the detector pulses and was evident in benchmark testing. For all
simulations, it was assumed that

225

Ac, 221Fr, and 213Bi were in secular equilibrium and thus had

equal activities. The high-definition Monte Carlo simulations showed that both
exhibit peaks in the energy range of

225

221

Fr and

213

Bi

Ac gamma pulse height distribution. Because of the 12.5
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keV energy resolution of the NaI(Tl) detector, these peaks are summed to form a larger
composite photopeak resulting in greater net counts, and thus over-calculated activities.
Gamma spectroscopic measurements were performed using the NaI(Tl) scintillation
detector. All samples were measured after the calculated time to reach secular equilibrium, but
the resulting activities were not equal. Further, the sum of activities for all three species greatly
overestimated the ion chamber readings. Although the activities determined for the three isotopes
should theoretically be identical, discrepancies are the result of the low energy bin resolution of
the detector and the dead time count saturation. Using the measured ion chamber readings as
input to the Monte Carlo simulations (Figure 9) largely overestimated the measured NaI(Tl)
spectrum.
After minimizing the difference between each sample spectra and the Monte Carlo output,
an activity response function relationship was determined for the two detectors (Figure 11). Both
the Monte Carlo activity and the ion chamber reading represent the sum of the activities of 225Ac,
221

Fr, and

213

Bi. The plot shows a curve with a decreasing positive slope as the ion chamber

measurements increased beyond 148 kBq. This is a result of the NaI(Tl) dead time losses. As the
activity of a sample increases, more pulses are lost, leading to errors in counting. The
discrepancy between the low energy measured and simulated peaks in Figure 10 is also a result
of dead time effects. The ratio of simulated to measured peaks increases with increasing activity
because the Monte Carlo model does not account for dead time. Further, the disagreement in the
simulated and measured spectra in the low count region arises from the fact that the model
represents an idealized detector and does not account for the metallic impurities of a real
detector.
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Standard NIST-traceable samples of 225Ac are currently unavailable, so 225Ac obtained from
Oak Ridge was used as a surrogate calibration reference. These samples did not come with
uncertainty estimations. As measurements using the recommended dial number agreed with the
Oak Ridge surrogate reference samples to less than 10%, the readings of the ionization chamber
were considered reliable for the study carried out in this work. The scintillation detector’s
measured energy resolution and detection efficiency over the energy range of

225

Ac gamma

emissions (40-662 keV) agreed with other published studies and reports.92,101,105,106
Consequently, this detector was also considered to be calibrated in efficiency and energy for
225

Ac analysis. The calibration sources used were all less than 185 kBq. When calibrating the ion

chamber with sources with activity above 5.71 MBq, the error was less than 3%. When testing
with sources in the lower activity range, error in the measurements increased to 10%, which is
still within ANSI recommended tolerance. The measurement results showed that the responses
from these two detectors do not correlate well in the activity range of 70 to 450 kBq, even
though both detectors were calibrated for efficiency and energy resolution according to their
respective recommended methods. The Monte Carlo model developed herein corrects NaI(Tl)
measurements, allowing for a more accurate estimate of

225

Ac and daughter activities over a

range of activities useful for both pre-clinical and clinical use.

3.5 Conclusions
In this work, the

225

Ac activity response function between two commonly used instruments

was investigated, a range of activities (70 to 450 kBq) was identified, and a method was
developed using Monte Carlo simulations to correct scintillation detector measurements within
this range. The scintillation detector was calibrated in energy and efficiency using NIST-

43

traceable sources covering a broad energy range, while the ion chamber was calibrated in
efficiency using a surrogate calibration reference. The error of ion chamber measurements
increased with decreasing activity, but remained within the ANSI recommended value of 10%.
The NaI(Tl) performed poorly from 70 to 450 kBq. Therefore, a Monte Carlo model was built to
correct the NaI(Tl) measurements, thereby providing improved accuracy. The corrections
provided by the Monte Carlo model will provide a useful tool to make corrections to the activity
values measured by the well-type NaI(Tl) detector. This allows for the better quantification of
alpha-particle emitting radiopharmaceuticals and daughter byproducts in pre-clinical and clinical
studies. In this case, use of scintillation gamma spectroscopy will be the preferred method.
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CHAPTER FOUR:
MELANOCORTIN 1 RECEPTOR TARGETED ALPHA-PARTICLE THERAPY FOR
METASTATIC UVEAL MELANOMA

Note to Reader
This research was originally published in JNM. Narges K.Tafreshi, Christopher J.
Tichacek,Darpan N. Pandya, Michael L. Doligalski, Mikalai M. Budzevich, HyunJoo Kil,
Nikunj B. Bhatt, Nancy D. Kock, Jane L. Messina, Epifanio E. Ruiz, Nella C. Delva, Adam
Weaver, William R. Gibbons, David C. Boulware, Nikhil I. Khushalani, Ghassan El-Haddad,
Pierre L. Triozzi, Eduardo G. Moros, Mark L. McLaughlin, Thaddeus J. Wadas, David L. Morse.
Melanocortin 1 Receptor Targeted Alpha-Particle Therapy for Metastatic Uveal Melanoma. J
Nucl Med. 2019 Aug;60(8):1124-1133.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

4.1 Introduction
Uveal melanoma is the most common primary intraocular malignancy and differs from
the more common cutaneous melanoma in terms of risk factors, primary treatment, anatomic
spread, molecular changes and response to systemic therapy 107,108. Patients that develop uveal
melanoma metastases, primarily in the liver, have a very poor prognosis, with a median survival
of about one year. Because uveal melanomas have different characteristic mutations compared
to cutaneous melanomas, targeted therapies that have been effective for cutaneous melanoma,
e.g. BRAF, are not indicated 109. Immune checkpoint inhibition therapies that are successful in
cutaneous melanoma have had poor efficacy in ocular melanoma with less than 10% of patients
responding and with rapid recurrence 109.
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The melanocortin 1 receptor (MC1R) is highly expressed in uveal melanoma metastases
110

. MC1R is a member of a family of five G protein coupled melanocortin receptors, four of

which bind melanocyte-stimulating hormone (MSH) and related ligands (MC1R, 3R, 4R & 5R)
111

. Unlike the other members of this G protein family, MC1R is not expressed in most normal

human tissues 112, lessening concern for therapy-related toxicity. Although expression is found
in the brain 113 and normal melanocytes 114, this is not a major concern as conjugates can be
designed to not cross the blood brain barrier and in the most severe cases of melanocyte loss, the
most serious symptom is vitiligo 115. MC1R expression has been reported on activated
monocytes, macrophages and dendritic cells derived from monocytes 116. This is also not a
significant concern since the population of activated monocytes and macrophages can be
replenished within days and lymphoid dendritic cells, which do not express MC1R, will not be
depleted. MC1R is highly polymorphic 117, but the wild-type frequency is ~50% 114 and the most
common mutations occur with a frequency of 21.5% in cytoplasmic domains, 19.7% in
transmembrane domains and 0% in the extracellular domain 117. Hence, a large majority of
patients will have an MC1R isoform that is suitable for ligand binding. A MC1R specific ligand
(MC1RL) and conjugates were previously developed with high specificity (>200 fold) and
affinity (0.2-0.4 Nm Ki) for MC1R 118,119. A fluorescent-dye conjugate was rapidly internalized
by MC1R expressing tumor cells, does not cross the blood brain barrier and is rapidly cleared
from circulation 113.
Herein is reported the preclinical development and testing of a novel MC1R targeted
radiopharmaceutical, 225Ac-DOTA-MC1RL, for targeted α-particle therapy (TAT)120,121 of uveal
melanoma. Alpha-particle emissions consist of di-cationic helium nuclei (He2+) that have high
linear energy transfer and a short mean free path of only a few cell diameters (< 100 µm) in

46

tissue 122.

225

Ac is an α-particle emitting radionuclide that has a 10 day half-life 123, four α-

emissions in its decay chain and high (28 MeV) total energy release 124.

4.2 Materials and Methods
4.2.1 Compound Synthesis and Loading with Lanthanide
MC1RL 119 was synthesized according to a conventional NαFluorenylmethyloxycarbonyl (Fmoc) peptide synthesis strategy, except the Fmoc-Lys(Alloc)-OH
was coupled to allow orthogonal alloc deprotection of the linker on the epsilon amino group of
the lysine following the linear peptide synthesis. The alloc group is removed and Fmocaminohexanoic acid linker and tri-t-butyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate
(DOTA, TCI) were coupled sequentially using O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HCTU) activation. The DOTA-MC1RL peptide was
cleaved from the resin with a cocktail of trifluoroacetic acid (TFA, Chem-Impex International),
water (H2O), and triisopropylsilane (TIS, Sigma-Aldrich) (95:2.5:2.5, v/v), precipitated in cold
diethyl ether, pelleted/decanted, and lyophilized. The crude white powder was purified by a
reverse-phase high-performance liquid chromatography (HPLC, Agilent) and characterized by
both MALDI-TOF mass spectroscopy (JEOL) and analytical HPLC. A scrambled peptide ligand
(DOTA-SP) was synthesized by changing the order of amino acids (sequence: 4-Phenylbutyric
Acid-Trp-Gly-His-Arg-(D)-Phe-Lys(Aminohexanoic Acid-DOTA)-CONH2). The Eu-DTPAMC1RL was synthesized as described before 125 except that MC1RL was used as the binding
ligand. Competition binding assays were performed as previously described using the EuDTPA-NDPα-MSH ligand. The Eu-DTPA-MC1RL binding affinity was determined using
saturation binding assays. To determine MC1RL binding affinity for murine MC1RL, saturation
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binding assays were performed using the Eu-DTPA-MC1RL and B16-F10 murine melanoma
cells with high expression of murine MC1R 118.

4.2.2 Cell Culture and Characterization
Uveal melanoma cell lines were acquired: (OCM1, OCM3 and OCM8 from Dr. KanMitchel, University of Southern California; OMM1 from Dr. Gregorius P. Luyten, University
Hospital at Rotterdam; and MEL270, MEL290 and OMM2.3 from Timothy Murray, Bascom
Palmer Eye Institute), and grown in RPMI medium, 10% fetal bovine serum, 100 units/Ml
penicillin, 100 mg/Ml streptomycin, 1% 200 Mm L-Glutamine, 1% 100 Mm sodium Pyruvate,
1% MEM Essential Vitamin Mixture (100X), 1% NEAA Mixture (100X) and 1% 1M HEPES in
5% CO2 at 37°C. A375, A375/MC1R human cutaneous melanoma cells and Hek293/MC1R
cells were obtained and grown as before 118,126. Cells were authenticated per American Type
Culture Collection (ATCC) guidelines 127, monitored for original morphology, tested for
mycoplasma (MycoAlert kit, Lonza) and only passage numbers <25 cells were used. MC1R
expression and receptor number were determined as previously described 118,119 except that EuDTPA-MC1RL was used for saturation binding.

4.2.3 Radiochemical Synthesis and Characterization
DOTA-MC1RL or DOTA-SP (10 μg/10 Μl water), 225Ac(NO3)3 (3.4 MBq), 90 Μl of
water and 10 Μl of 20% L-ascorbic acid were added to a 1.5 Ml tube followed by Ph adjustment
to 5.5-6 (1 M Tris buffer;10-12 Μl) and incubation at 60ºC for 1 h (Figure 15).
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Figure 12. Radiochemical synthesis of 225Ac-DOTA-MC1RL.76

Specific activity was calculated using a standard method 128. Radiochemical purity was assessed
24 h after collection by gamma counter and in vitro serum stability was determined by adding 50
µL of 225Ac-DOTA-MC1RL (2072 kBq) to 1 ml of human serum (n=4), incubated at 37°C for 10
days and quantified at multiple time points by TLC scanner and gamma-counter using
established methods 129.

4.2.4 Animal Studies
All protocols were approved: University of South Florida IACUC protocol IS00000805
and Wake Forest University Health Sciences IACUC protocol A11-144. Male and Female
animals were used. Sprague-Dawley rats, 10-12 weeks old, 200-250 g were purchased with
jugular vein catheters installed (Charles River). Non-tumor studies used BALB/c mice (10-12
weeks, 18-22 g, Charles River). Severe combined immunodeficient (SCID) mice (6-8 weeks,
15-20 g, Charles River) were used for xenografting cell lines. Tail vein catheters were used for
agent administration to mice.
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For xenografting, 1 × 106 cells in 80 µl of PBS and 20 µl of Matrigel (phenol red free,
Corning) were injected subcutaneously into the flank. Tumor volumes were determined by
caliper using the formula: volume = (length × width2)/2 for A375 and A375/MC1R, and volume
= (length × width × height)/2 for MEL270 tumors, which were initially flat with a gradual shift
to a rounded shape.

4.2.5 Histology and Immunohistochemistry (IHC)
Excised tissues were prepared for histology, hematoxylin and eosin (H&E), MC1R IHC
staining, and slide scanning were performed as previously described 118. Metastasis burden was
determined using images of 3 sections (25%, 50% and 75%) through each liver and lung.
Metastasis area was determined by segmentation using intensity and size threshold classifiers on
the triple red channel (Visiopharm software version 6.7.0.2590, Denmark), total tissue area was
determined with an intensity threshold classifier on the I intensity channel and the percent
metastasis calculated.
To quantify MC1R expression in tumors, images from serial H&E and IHC sections were
analyzed using Visiopharm 2017.7. Each serial section pair (H&E and IHC) were aligned using
the tissue align module and viable tumor segmented by thresholding the hematoxylin
channel. A multi-threshold marker area analysis was then performed within the viable tumor
region on each IHC image. Each pixel was placed into 4 categories (Negative, Weak, Moderate,
Strong) based on thresholds set by a pathologist and percentages of each category were
normalized by total area of interest.
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4.2.6 Maximum Tolerated Dose (MTD)
The MTD study was performed as previously described 129.

4.2.7 Measurement of Activity
Since α-particles from 225Ac cannot be directly measured in tissue due to the short mean
free path 124, 225Ac α-activities were estimated using measurements of related gamma emissions.
For the initial MTD study, syringes were prepared with a range of activities as determined by the
gamma counter (Wallac 1470 Wizard , Perkin-Elmer). For subsequent studies, syringes were
prefilled with 148 kBq ±10% (per appendix E of the BioDex manual) of 225Ac-conjugate activity
using a dose calibrator (BioDex Atomlab 500). Activities were measured for 2 mins using dial
number 38.2 as recommended by Biodex. Activities of 225Ac, and the 221Fr and 213Bi daughter
products 124 were measured by acquiring isomeric gamma spectra (Figure 9) prior to
administration using a 4π well-type wipe-test gamma counter (BioDex Atomlab 500). Activities
(225Ac) were calculated using factors for gamma ray abundance per α-decay using calibration
parameters and correction coefficients from Appendices A and E of the instrument manual. A
full energy window (0-800 keV) was used for spectra acquisition that included gamma counts
from 225Ac (99.8 keV peak, 1% abundance), and two gamma emitting daughters, 221Fr (218.1
keV peak, 11.4 % abundance) and 213Bi (440.5 keV peak, 25.9 % abundance) 130. The αactivities were determined by fitting each peak with a multi-Gaussian fit and integrating to
determine the net number of counts while incorporating the acquisition time. Spectra were
acquired ≥24 h post-radiosynthesis or tissue rendering ensuring that 225Ac and daughters were in
secular equilibrium 131. Activity remaining in the syringe and catheter post-injection were
calculated and subtracted to determine net administered activity.
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4.2.8 Blood Pharmacokinetics
Sprague-Dawley rats were weighed prior to injection with radioactivity and injected
with 148 kBq (±10%) of 225Ac-DOTA-MC1RL in the syringe. Serial blood draws (45 µL) were
taken from 5 min to 24 h post-injection (p.i.).

225

Ac α-activity was calculated as described

above. Data were fitted using an exponential decay nonlinear regression.

4.2.9 Biodistribution
Non-tumor bearing BALB/c mice, or SCID mice bearing MEL270 xenografts (160-650
mm3), or A375 and A375/MC1R bilateral xenograft tumors (189-1680 mm3) were intravenously
administered 148 kBq (±10%) of 225Ac α-activity in the syringe. Tissues were rendered and
weighed at multiple time-points between 24 h to 3 weeks p.i.. For each tissue, 225Ac, 221Fr and
213

Bi α-activities were calculated as described above and reported as percent injected activity per

gram (%IA/g).

4.2.10 Radiation Dosimetry (RD)
Tissue BD data for the different tissues were fitted using an exponential decay nonlinear
regression and dosimetry calculations were performed for 225Ac, 221Fr , 217At, 213Bi, and 213Po
using the generalized internal dosimetry schema of the Medical Internal Radiation Dose (MIRD)
Committee for α-particle emitters 46,132. The β- decay branching ratio for 217At to 217Rn is only
0.01%, therefore it was assumed that all decays of 217At were by α-emission to 213Bi. The
branching ratios for decay of 213Bi to 213Po (98%) or 209Tl (2%) were included in the calculation.
Due to the relatively low linear energy transfer and the small dimensions of the target tissues,
the β- emissions from 217At, 213Bi, 209Tl and 209Pb were assumed negligible and were not included
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in the calculations 133. The following assumptions were made: 1) uniform distribution of
activity in the tissue volume; 2) no α-particles escaped from the source tissue due to the short
range; and 3) electron and photon contributions were assumed to be negligible compared to αparticle energy deposition 133. It was also assumed that α-particles from 221Fr (4.9 min T1/2),
217

At (32.2 ms T1/2 ), 213Bi (46 min T1/2) and 213Po (4.2 µs T1/2) were deposited in the same

location as 225Ac (10 d T1/2) due to the relatively shorter half-lives of these daughter isotopes.
Although 217At and 213Po do not have detectable gamma emissions, under the assumption that the
decay chain had reached secular equilibrium, the accumulated activity of these two daughters
would equal that of 221Fr and 213Bi, respectively. The total absorbed α-particle dose was
calculated from the summation of doses from 225Ac, 221Fr, 217At, 213Bi and 213Po.

4.2.11 Anti-tumor Efficacy
Tumor bearing mice (n=11/group) were injected with activities of 225Ac-DOTA-MC1RL
or 225Ac-DOTA-SP, cold La-DOTA-MC1RL, or saline solution (0.9%, Cardinal
Pharmaceuticals). Surpassing 2000 mm3 tumor volume was the experimental endpoint unless
clinical endpoints, e.g. 20% weight loss, tumor ulceration, hunched back, lack of grooming or
lethargy were observed. Metastasis formation was identified by necropsy.

4.2.12 Statistical Analysis
The T-test was used for the MTD study. The following analyses were used for
comparison of the efficacy study groups: Kaplan-Meier for time to endpoint, a mixed model
analysis for tumor growth change, a paired Wilcoxon Signed Rank test for initial decrease in
tumor volume, the Fisher’s Exact test with corrections for multiple testing using the Holm
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stepdown method for metastasis burden, and non-parametric Kruskal-Wallis test for IHC
staining.

4.3 Results
4.3.1 Synthesis and Characterization of Parent Compound and Lanthanide Chelates
The unmetallated DOTA-MC1RL was synthesized and, since there are no nonradioactive isotopes of Ac, the analogous La-DOTA-MC1RL chelate was prepared for use as a
non-radioactive control 129,134. Both DOTA-MC1RL and La-DOTA-MC1RL had high binding
affinity for human MC1R, 0.24 ± 0.20 and 0.23 ± 0.18 Nm Ki respectively (Supplemental Fig.
9A). The binding affinity of Eu-DTPA-MC1RL to human MC1R was determined to be 4.4 ± 2.3
Nm Kd. Lower, 1.3 µM Kd affinity was observed for Eu-DTPA-MC1RL binding to murine
MC1R. The scrambled peptide controls, La-DOTA-SP and Eu-DOTA-SP, did not bind.

4.3.2 Radiosynthesis and Characterization of 225Ac Radiopharmaceutical
Radiochemical purity of 99.8% and specific activity of 181.3 ± 92.5 kBq/µg and 140.6 ±
55.5 µkBq/µg for 225Ac-DOTA-MC1RL and 225Ac-DOTA-SP, respectively, were observed. In
vitro serum stability was high, with 90% intact after 10 days (Table 4)
Table 4. In vitro serum stability of 225Ac-DOTA-MC1RL.76
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4.3.3 MC1R Expression on Uveal Melanoma Cell Lines and Xenograft Tumors
MC1R Mrna and protein expression were confirmed in a set of uveal melanoma cell
lines. Only MEL270, OMM2.3 and OMM1 cells carry the GNAQ or GNA11 mutations found in
nearly all uveal melanomas 135. The MEL270 and OMM1 cells formed tumors in
immunocompromised mice and all xenografts had high and uniform MC1R protein expression.

4.3.4 Receptor Number for Tumor Cell Lines
MEL270 cells were selected for the in vivo studies and it was determined that MEL270
cells have 410,000 receptors per cell, which is a higher level of endogenous expression than the
engineered A375/MC1R cells that have 75,000 receptors per cell 118. The parental A375
melanoma cell line has extremely low expression with 400 ± 93 MC1R per cell 136.

4.3.5 In vitro MC1R-specific Cytotoxicity
Cytotoxicity assays were performed with the goal of demonstrating target-specific
cytotoxicity. Assay conditions were not optimized to demonstrate maximal toxicity.
Significantly reduced proliferation (p < 0.0001) was observed in uveal melanoma cells and the
engineered A375/MC1R cells treated with 225Ac-DOTA-MC1RL relative to the untargeted
225

Ac-DOTA-SP or PBS controls. All cell lines also had a significant (p < 0.001) response to

incubation with 225Ac-DOTA-SP relative to PBS. However, there was no significant difference
in A375 cell proliferation (extremely low MC1R) when treated with either the targeted or
untargeted radiopharmaceutical. These results demonstrate MC1R-specific cytotoxicity. Assay
replicates yielded comparable results.
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4.3.6 Maximum Tolerated Dose (MTD)
The MTD was evaluated in immune-competent non-tumor bearing BALB/c mice (n =
5/cohort). Cohorts received a single i.v. injection of 225Ac-DOTA-MC1RL over the range of 0148 kBq in the syringe. At completion of the study (>11 225Ac half-lives, 118 days post
injection) serum and tissues (adipose, bone, cecum, colon, duoden, esophageal, heart, ileum,
kidney, liver, lung, lymph nodes, muscle, pancreas, small intestine, spleen and stomach) were
collected for histology and then blindly examined by a veterinary pathologist to assess radiationinduced tissue damage. There was no remarkable damage observed in any of the tissues, e.g. the
control kidneys had minimal multifocal interstitial fibrosis and minimal medullary protein in
tubules which were both considered to be incidental findings. The incidental minimal medullary
protein was also found in some kidneys from the groups that received treatment activities, but
each treatment group also included kidneys that were within normal limits of all types of
damage. The renal cortex of one kidney from the group with the highest administered activity
had focal extracellular cortical hyaline substance which was healing and was considered to be an
incidental finding. Blood urea nitrogen (BUN) and creatinine, which are important indicators of
renal function, were also determined and were not significantly elevated among the groups
(Figure 16 B&C). All animals had gained weight by the end of the study, albeit less weight was
gained by animals at the highest dose level relative to the lowest (Figure 13A).
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Figure 13. MTD study for non-tumor bearing mice: (A) Percent weight gain, (B) BUN and (C)
blood creatinine.76

4.3.7 Pharmacokinetics and Biodistribution
In rats, 225Ac-DOTA-MC1RL rapidly cleared (<15 min p.i.) from blood circulation
(Figure 14).

Figure 14. Plot of rat blood clearance. Exponential decay non-linear regression line fit of 225Ac
alpha activity in rat blood over time, following intravenous administration of 225Ac-DOTAMC1RL (n=4 rats).76

Following administration to non-tumor bearing BALB/c mice, 225Ac activities were
observed primarily in clearance tissues. At 24 h p.i. of 225Ac-DOTA-MC1RL, the liver, kidneys,
spleen and intestine had 21.2 ±2.8, 6.9±0.9, 2.9±0.8 and 2.9±2.0 %IA/g, while negligible activity
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was observed in the other tissues measured. Activity had largely cleared from the tissues in 1-3
weeks (Figure 15A).

Figure 15. Biodistribution of 225Ac-DOTA-MC1RL. 225Ac, 221Fr and 213Bi activities in tissues
from (A) non-tumor bearing BALB/c mice (n=6 per time point) and (B) SCID mice bearing
MEL270 human uveal melanoma tumors (n=5 per time point).76

For tumor-bearing animals, activity was retained in MC1R positive tumors, i.e. MEL270 (Figure
15B) and A375/MC1R tumors (Figure 16A) that had 3.6±1.2 and 2.8±0.8 %IA/g, respectively,
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compared to the nominal 0.30±0.1 %IA/g in the MC1R negative A375 tumors at 24 h postinjection. The clearance tissues in tumor bearing animals had lower activities compared to
clearance tissues in the non-tumor bearing mice, e.g. 14.4±1.7 %IA/g in the livers of MEL270
tumor-bearing mice at 24 h (Figure 15B), compared to the 21.2 ±2.8 %IA/g observed in the nontumor bearing mice (Figure 15A). The 225Ac-DOTA-SP tumor distribution in the bilateral A357
and A375/MC1R model was also determined and, as expected, uptake was minimal and did not
differ among the positive and negative A375 tumors (Figure 16B).

Figure 16. Biodistribution of (A) 225Ac-DOTA-MC1RL and (B) 225Ac-DOTA-SP in bilateral
A375 and A375/MC1R tumors (n=5 per time point).76

The distribution of 221Fr and 213Bi were also determined (Figures 15 & 16). However, since
225

Ac and daughters are at secular equilibrium by 24 h p.i. and the 221Fr and 213Bi atoms present
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during injection will be mostly decayed, the 221Fr and 213Bi detected in the samples are from
decay of the 225Ac taken into the tissues.

4.3.8 Radiation Dosimetry
BD data were fitted, and clearance kinetics, tissue biological half-life, accumulated
activity, and absorbed dose/injected activity (Gy/kBq) were estimated for each radionuclide in
each tissue for non-tumor bearing and MEL270 tumor bearing mice (Tables 5&6).
Table 5. Radiation dosimetry and clearance kinetics parameters for 225Ac-DOTA-MC1RL in
non-tumor bearing BALB/c mice.76
225

Ac
Blood

Brain

Heart

Intestine

Kidney

Liver

Lung

Muscle

Skin

Spleen

ND

0.0065

0.0161

1.9113

0.7647

7.6597

0.0512

0.0044

0.0483

0.0426

Decay rate constant, λeff (h )

ND

0.0070

0.0030

0.0060

0.0060

0.0040

0.0030

0.0030

0.0050

0.0030

Decay half-life, Teff (days)

ND
ND
ND

4.1259
0.7621
0.0002

9.6270
3.8089
0.0023

4.8135
260.3419
0.0102

4.8135
104.1599
0.0300

7.2203
1484.6038
0.1485

9.6270
12.1242
0.0042

9.6270
1.0529
0.0004

5.7762
7.7927
0.0024

9.6270
10.0784
0.0092

Parameter
Initial activity/organ, Ao (kBq)
-1

Accumulated activity/organ, Ã (kBq*h)
Absorbed dose/injected activity (Gy/kBq)

221

Fr

Blood

Brain

Heart

Intestine

Kidney

Liver

Lung

Muscle

Skin

Spleen

0.0153

0.0222

0.0349

1.9927

1.3795

8.4464

0.0723

0.0211

0.0705

0.0647

Decay rate constant, λeff (h )

0.0010

0.0030

0.0050

0.0070

0.0080

0.0040

0.0020

0.0030

0.0040

0.0040

Decay half-life, Teff (days)

28.8811 9.6270
5.6907 5.2622
0.0022 0.0013

5.7762
5.6292
0.0037

4.1259
232.2869
0.0098

3.6101
139.2517
0.0434

7.2203
1637.0734
0.1770

14.4406
21.2642
0.0080

9.6270
4.9899
0.0018

7.2203
13.6614
0.0045

7.2203
12.5317
0.0124

Parameter
Initial activity/organ, Ao (kBq)
-1

Accumulated activity/organ, Ã (kBq*h)
Absorbed dose/injected activity (Gy/kBq)
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Parameter
Initial activity/organ, Ao (kBq)

At

Blood

Brain

Heart

Intestine

Kidney

Liver

Lung

Muscle

Skin

Spleen

0.0153

0.0222

0.0349

1.9927

1.3795

8.4464

0.0723

0.0211

0.0705

0.0647

Decay rate constant, λeff (h )

0.0010

0.0030

0.0050

0.0070

0.0080

0.0040

0.0020

0.0030

0.0040

0.0040

Decay half-life, Teff (days)

28.8811 9.6270
5.6907 5.2622
0.0025 0.0014

5.7762
5.6292
0.0042

4.1259
232.2869
0.0110

3.6101
139.2517
0.0486

7.2203
1637.0734
0.1983

14.4406
21.2642
0.0090

9.6270
4.9899
0.0021

7.2203
13.6614
0.0050

7.2203
12.5317
0.0139

-1

Accumulated activity/organ, Ã (kBq*h)
Absorbed dose/injected activity (Gy/kBq)

213

Bi

Blood

Brain

Heart

Intestine

Kidney

Liver

Lung

Muscle

Skin

Spleen

0.0236

0.0195

0.0309

1.8886

1.0318

6.5122

0.0717

0.0152

0.0627

0.0511

Decay rate constant, λeff (h )

0.0010

0.0010

0.0020

0.0050

0.0040

0.0040

0.0020

0.0020

0.0030

0.0030

Decay half-life, Teff (days)

28.8811 28.881
8.7917 7.2573
0.0001 0.0000

14.4406
9.0914
0.0001

5.7762
304.6111
0.0002

7.2203
199.9839
0.0012

7.2203
1262.1858
0.0025

14.4406
21.0948
0.0001

14.4406
4.4603
0.0000

9.6270
14.8376
0.0001

9.6270
12.1064
0.0002

Parameter
Initial activity/organ, Ao (kBq)
-1

Accumulated activity/organ, Ã (kBq*h)
Absorbed dose/injected activity (Gy/kBq)

60

Table 5. (Continued)
213

Po

Blood

Brain

Heart

Intestine

Kidney

Liver

Lung

Muscle

Skin

Spleen

0.0236

0.0195

0.0309

1.8886

1.0318

6.5122

0.0717

0.0152

0.0627

0.0511

Decay rate constant, λeff (h )

0.0010

0.0010

0.0020

0.0050

0.0040

0.0040

0.0020

0.0020

0.0030

0.0030

Decay half-life, Teff (days)

28.8811 28.881
8.7917 7.2573
0.0044 0.0023
Blood
Brain

14.4406
9.0914
0.0079
Heart

5.7762
304.6111
0.0168
Intestine

7.2203
199.9839
0.0811
Kidney

7.2203
1262.1858
0.1778
Liver

14.4406
21.0948
0.0103
Lung

14.4406
4.4603
0.0021
Muscle

9.6270
14.8376
0.0063
Skin

9.6270
12.1064
0.0156
Spleen

0.0092

0.0183

0.0481

0.2042

0.7042

0.0317

0.0064

0.0182

0.0512

Parameter
Initial activity/organ, Ao (kBq)
-1

Accumulated activity/organ, Ã (kBq*h)
Absorbed dose/injected activity (Gy/kBq)
Total absorbed dose/injected Activity (Gy/kBq)

0.0053

The effective decay half-lives (Teff) calculated for 225Ac in tissues, e.g. 7.2 d in liver, were
shorter than the radiodecay half-life of 225Ac (10 d) indicating biological clearance. The
calculated total absorbed dose per injected activity (Gy/kBq) for 225Ac-DOTA-MC1RL was
minimal in all tissues except clearance organs and positive tumor. Since the positive tumors
shrank rapidly in response to the treatment and the total absorbed dose values were extrapolated
from data collected over a two week period, the dose values for the tumors are likely subdued
relative to the clearance organs which did not have appreciable cellular toxicity at the
administered activities. The total absorbed dose in the liver was generally lower in mice with
tumors compared to non-tumor mice, e.g. 0.284 Gy/kBq and 0.704 Gy/kBq, respectively.
Table 6. Radiation dosimetry and clearance kinetics for 225Ac-DOTA-MC1RL in SCID mice
bearing MEL270 tumors.76
225

Blood

Bone

0.0010

0.0172

Decay rate constant, λeff (h )

0.0010

Decay half-life, Teff (days)

28.8811

Parameter
Initial activity/organ, Ao (kBq)

Brain

Heart

Ac

Intestine

Kidney

Liver

Lung

Muscle

Skin

Spleen

Tumor

0.0031 0.0151

0.3026

0.6417

4.8193

0.0265

0.0042

0.0242

0.0228

0.0518

0.0030

0.0020 0.0050

0.0130

0.0050

0.0060

0.0050

0.0020

0.0020

0.0040

0.0080

9.6270

14.4406 5.7762

2.2216

5.7762

4.8135

5.7762

14.4406 14.4406

7.2203

3.6101

0.2726

3.2443

0.6873 2.1154

16.7417

89.9040 588.513

3.7089

0.9236

5.3441

3.6979

4.9055

0.0001

0.0041

0.0003 0.0020

0.0012

0.0273

0.0025

0.0007

0.0010

0.0107

0.0045

-1

Accumulated activity/organ, Ã
(kBq*h)
Absorbed dose/injected activity
(Gy/kBq)

61

0.0662

Table 6. (Continued)
221

Blood

Bone

0.0036

0.0185

Decay rate constant, λeff (h )

0.0017

Decay half-life, Teff (days)

16.9889

Parameter
Initial activity/organ, Ao (kBq)

Brain

Heart

Fr

Intestine

Kidney

Liver

Lung

Muscle

Skin

Spleen

Tumor

0.0059 0.0192

0.2655

0.6167

4.4828

0.0495

0.0071

0.0362

0.0257

0.0806

0.0030

0.0010 0.0030

0.0090

0.0040

0.0060

0.0040

0.0020

0.0020

0.0010

0.0070

9.6270

28.8811 9.6270

3.2090

7.2203

4.8135

7.2203

14.4406 14.4406

28.881

4.1259

0.8370

3.4960

1.5396 3.6259

22.3311

99.8475 547.425

8.0162

1.5699

8.0166

6.7303

8.6407

0.0002

0.0047

0.0007 0.0037

0.0017

0.0328

0.0058

0.0014

0.0017

0.0211

0.0086

-1

Accumulated activity/organ, Ã
(kBq*h)
Absorbed dose/injected activity
(Gy/kBq)

217

Blood

Bone

0.0036

0.0185

Decay rate constant, λeff (h )

0.0017

Decay half-life, Teff (days)

16.9889

Parameter
Initial activity/organ, Ao (kBq)

Brain

Heart

0.0666

At

Intestine

Kidney

Liver

Lung

Muscle

Skin

Spleen

Tumor

0.0059 0.0192

0.2655

0.6167

4.4828

0.0495

0.0071

0.0362

0.0257

0.0806

0.0030

0.0010 0.0030

0.0090

0.0040

0.0060

0.0040

0.0020

0.0020

0.0010

0.0070

9.6270

28.8811 9.6270

3.2090

7.2203

4.8135

7.2203

14.4406 14.4406

28.881

4.1259

0.8370

3.4960

1.5396 3.6259

22.3311

99.8475 547.425

8.0162

1.5699

8.0166

6.7303

8.6407

0.0003

0.0053

0.0007 0.0041

0.0019

0.0367

0.0065

0.0015

0.0019

0.0236

0.0097

-1

Accumulated activity/organ, Ã
(kBq*h)
Absorbed dose/injected activity
(Gy/kBq)

213

Parameter
Initial activity/organ, Ao (kBq)

0.0746

Bi

Blood

Bone

Brain

Heart

Intestine Kidney

Liver

Lung

Muscle

Skin

Spleen

Tumor

0.0016

0.0133

0.0027

0.0082

0.2160

0.5664

3.9089

0.0175

0.0017

0.0240

0.0131

0.0381

-1

Decay rate constant, λeff (h )
Decay half-life, Teff (days)
Accumulated activity/organ, Ã
(kBq*h)
Absorbed dose/injected activity
(Gy/kBq)

0.0013

0.0020

0.0007

0.0040

0.0100

0.0040

0.0060

0.0060

0.0020

0.0050

0.0030

0.0060

22.2163

14.4406 41.2588

7.2203

2.8881

7.2203

4.8135

4.8135

14.4406

5.7762

9.6270

4.8135

0.4096

2.9358

1.3342

16.2384 91.7024 477.346

2.1354

0.3859

3.3617

2.4736

4.6565

0.7531

2.20E-06 7.39E-05 5.96E-06 2.51E-05 2.32E-05 5.61E-04 1.08E-03 2.88E-05 6.19E-06 1.32E-05 1.44E-04 8.68E-05
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Parameter
Initial activity/organ, Ao (kBq)

Po

Blood

Bone

Brain

Heart

Intestine Kidney

Liver

Lung

Muscle

Skin

Spleen

Tumor

0.0016

0.0133

0.0027

0.0082

0.2160

0.5664

3.9089

0.0175

0.0017

0.0240

0.0131

0.0381

-1

Decay rate constant, λeff (h )

0.0013

0.0020

0.0007

0.0040

0.0100

0.0040

0.0060

0.0060

0.0020

0.0050

0.0030

0.0060

Decay half-life, Teff (days)

22.2163

14.4406 41.2588

7.2203

2.8881

7.2203

4.8135

4.8135

14.4406

5.7762

9.6270

4.8135

Accumulated activity/organ, Ã
(kBq*h)

0.4096

2.9358

0.7531

1.3342

16.2384 91.7024 477.346

2.1354

0.3859

3.3617

2.4736

4.6565

Absorbed dose/injected activity
(Gy/kBq)

0.0002

0.0052

0.0004

0.0018

0.0016

0.0756

0.0020

0.0004

0.0009

0.0101

0.0061

Blood

Bone

Brain

Heart

Liver

Lung

Muscle

Skin

Spleen

Tumor

Total absorbed dose/injected Activity
(Gy/kBq)

0.0007

0.0193

0.0021

0.0392

Intestine Kidney

0.0115
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0.0065

0.1366

0.2842

0.0168

0.0040

0.0056 0.0656

0.0290

4.3.9 Anti-tumor Efficacy
SCID mice bearing MEL270 tumors (124±36 mm3 pre-treatment tumor volumes) were
injected with a single administration of 225Ac-DOTA-MC1RL (92.5±9.3 kBq), 225Ac-DOTA-SP
(99.9±9.9 kBq), La-DOTA-MC1RL (1 pmol/mouse) or saline. Representative images show
much smaller tumors in treated mice relative to controls (Fig. 17A) and tumor volumes
decreased immediately after treatment relative to controls ( p=0.001) prior to eventual regrowth
(Figure 17B).

Figure 17. Efficacy study in mice bearing MEL270 tumors: (A) Representative images of
tumors (outlined); (B) initial tumor growth volumes; (C) Kaplan-Meier plots.76
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Treated mice had a significantly delayed time to experimental or clinical endpoint (p < 0.001)
with a median survival of 148 days, compared to the median survival of control groups (79-108
d) and differences among the controls were not significant (Figure 17C). In this study, some
animals were euthanized due to reaching clinical endpoints instead of the experimental endpoint.
Some of the animals that reached clinical endpoints had metastases in the liver or lungs and
metastasis burden was significantly lower in the 225Ac-DOTA-MC1RL treated group relative to
the controls (p = 0.024) (Figure 18 A&B).

Figure 18. (A-B) Metastasis study in MEL270 uveal melanoma mouse model and (C-D) MC1R
expression in tumors reaching endpoints from each treatment group. (A) Representative H& E
staining and corresponding threshold segmentations of sections containing liver and lung
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metastases (Cold=La-DOTA-MC1RL, Scrambled=untargeted, treated=225Ac-DOTA-MC1RL),
blue=normal tissue and green=metastasis; and (B) quantified metastasis burden. (C-D) MC1R
IHC staining of MEL270 tumors after reaching endpoints.76

Mice bearing A375/MC1R tumors (240±110 mm3 pretreatment volume) were also injected with
either sterile saline, La-DOTA- MC1RL, 107.3±11.1 kBq of 225Ac-DOTA-SP or 59.2±5.9 kBq
of 225Ac-DOTA-MC1RL and significant decreases in tumor volume (p = 0.005) and tumor
growth delay (p < 0.0001) were observed. Some tumors that disappeared did not recur and those
mice lived their natural lifespan.

Figure 19. Efficacy study in mice bearing A375/MC1R tumors: (A) Representative images of
tumors (outlined); (B) initial tumor growth volumes; and (C) Kaplan-Meier plots.76

After tumors reached an endpoint, MC1R staining was quantified and the level of MC1R
expression was not significantly different in treated tumors that responded by shrinking prior to
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regrowth relative to control tumors (p = 0.60 MEL270 and p=0.82 A375/MC1R) (Figure 18
C&D).

4.4 Discussion
We have developed and evaluated a novel MC1R-targeted radiopharmaceutical, 225AcDOTA-MC1RL, for TAT of metastatic uveal melanoma. The choice of using a peptide targeting
ligand is reinforced by the recent pre-clinical and clinical successes of TAT radio-peptides
99,120,121,137,138

. Another group has also reported the development of a peptide-based TAT, 212Pb-

CCMSH, that is targeted to melanocortin receptors for treatment of melanoma 139. However,
212

Pb-CCMSH was associated with renal toxicity. This is likely due to the use of an α-MSH

(melanocyte stimulating hormone) derivative targeting ligand as α-MSH has specificity for
multiple melanocortin receptor isoforms, including MC5R which is expressed in the human
kidney and lungs 112. The MC1RL targeting moiety used in the current work has specificity for
the MC1R isoform 119, greatly reducing the potential for renal toxicity. Another advantage of
225

Ac-DOTA-MC1RL compared to the 212Pb-TAT agent, is that 225Ac has greater cell killing

potential through generation of four α-particle emissions per radionuclide compared to the single
α-emission of 212Pb in their relative decay chains 25,139.
225

Ac-DOTA-MC1RL has high affinity for MC1R, high radiochemistry yield and purity,

high biostability and MC1R specific cytotoxicity in vitro. In vivo studies demonstrated low
toxicity, rapid blood clearance and uptake into MC1R positive tumors and clearance organs.
Biodistribution studies demonstrated that 225Ac remains in the compartments where 225AcDOTA-MC1RL was initially distributed, i.e. tumors and clearance organs, and the corresponding
clearance kinetics parameters and radiation dose delivered by all α-particle emitting
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radioisotopes in the decay chain were calculated. Considering the 10 d half-life of 225Ac, most of
the administered 225Ac-DOTA-MC1RL will have either been taken into tumor cells 113 or cleared
from the blood prior to decay. Hence, 225Ac-DOTA-MC1RL likely functions as an in vivo αparticle generator, concentrating α-emissions in the target tumor tissues with limited
translocation of daughter isotopes 99. This is consistent with the recent observations of efficacy
with low toxicity observed for an 225Ac-PSMA targeting small-molecule conjugate 140.
In vivo efficacy studies demonstrated significant tumor and metastasis growth delay, and
prolonged survival in human uveal and cutaneous melanoma xenograft models in mice following
a single treatment of 225Ac-DOTA-MC1RL, including some cures. Tumors that shrank and
regrew following treatment had the same MC1R expression levels as controls, suggesting that
multiple treatment regimens would increase efficacy.

4.5 Conclusion
We have developed and evaluated a novel MC1R-targeted radiopharmaceutical for TAT
of metastatic uveal melanoma. In vivo studies demonstrated low toxicity, rapid blood clearance,
uptake into MC1R positive tumors and clearance organs, significant tumor and metastasis
growth delay, and prolonged survival in human uveal melanoma xenograft models in mice
following a single treatment of 225Ac-DOTA-MC1RL. This novel radiopharmaceutical has
strong potential to benefit patients with metastatic uveal melanoma, which has had no significant
improvement in treatment in the last 20 years.
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CHAPTER FIVE:
BIODISTRIBUTION AND MULTI-COMPARTMENT PHARMACOKINETIC
ANALYSIS OF TWO TARGETED ALPHA PARTICLE THERAPIES

5.1 Introduction
Receptor-targeted cancer therapy using alpha-emitting radionuclides has become an area
of significant interest for both preclinical and clinical investigation.141 The interest in the use of
alpha particles to treat metastatic cancer arises from their favorable physical interactions in
tissue, i.e., short path length (50-100µm) and high linear energy transfer (LET) (80-100keV/µm),
which are the result of their large kinetic energy and 2+ charge.4 These properties allow for the
potential to target disseminated cancer cells through ligand conjugation and create irreparable
DNA double strand breaks and other intracellular damage while minimizing radiation dose to
non-targeted tissues.
The most common ocular malignancy, uveal melanoma, accounts for 85-95% of all
ocular melanoma cases.142 Despite favorable outcomes for local control, the five year survival
after metastasis is less than 1%, with a median survival time of 3.6 months post diagnosis.143
The melanocortin-1 receptor (MC1R) belongs to the melanocortin family of G protein coupled
receptors and has been shown to be predominantly expressed by melanoma and
melanocytes.144,145 MC1R has been shown to be overexpressed in malignant primary and
metastatic uveal melanoma cell lines with insignificant expression in other normal
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tissues.112,116,146 α-Melanocyte stimulating hormone (α-MSH), a tridecapeptide, is the most
potent naturally occurring melanotropic peptide for the activation of MC1R147 and is a potent
stimulator of the differentiation of pigmented melanoma cells.144 Radiolabeled peptide ligands
based on the sequence of α-MSH have been investigated, however these do not show selectivity
for MC1R.146 An MC1R specific ligand, MC1RL, with high specificity and affinity for MC1R
has been developed and tested.148,149 An MC1R targeted alpha emitting radiopharmaceutical,
225

Ac-DOTA-MC1RL, has been synthesized and tested in vivo showing promising results for

clinical translation.76
The quantity of radiopharmaceutical to be administered and resulting absorbed dose may
be determined based on a prediction of the biodistribution (BD), uptake, and clearance of the
drug over time in organs and tumors.150 Optimization of a radiotherapy consists of maximizing
tumor control while minimizing normal tissue complications. Pharmacokinetic (PK) modeling
using pre-clinical and clinical distribution data is a useful tool that can enable optimized
treatment by estimating transport properties of the radiopharmaceutical.151 By segmenting the
body into compartments which are related through differential equations, and placing measured
radioactivity concentrations in them, one can make predictions on the effectiveness of the
radiopharmaceutical. Typically, blood PK measurements are taken over time and a two
compartment model is constructed and solved with acquired samples.152 A novel multicompartmental PK model for a targeted alpha therapy could help to compare the BD , predict the
relative effectiveness of different TAT compounds and provide a basis for rejection early in the
developmental process.153 Many alpha emitting radionuclides cannot be directly imaged for
biodistribution analysis. The model could be used alongside a companion imaging agent for
patient specific treatment planning.
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Two versions of a therapeutic alpha radiopharmaceutical are being investigated: 225AcDOTA-Ahx-MC1RL (Ahx) and 225Ac-DOTA-di-D-Glu-MC1RL (di-D-Glu). In this study, the
BD in mice from each was assessed and a computational multi-compartment pharmacokinetic
PK model was developed to describe drug distribution and elimination rates.

5.2 Materials and Methods
5.2.1 MC1RL Peptide Synthesis
The MC1RL peptide with di-D-Glu linker was synthesized on Rink Amide resin (initial loading:
0.568 mmol/g) using Nα- Fluorenylmethyloxycarbonyl (Fmoc)-protecting amino acids and O(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU)/
Diisopropylethylamine (DIEA) strategy. After the resin was swollen in Dichloromethane (DCM)
for 30 minutes, the Fmoc protecting group was removed with 2% 1,8-Diazabicyclo(5.4.0)undec7-ene (DBU) in Dimethylformamide (DMF) (2 × 5 min). The resin was washed with N-methyl2-pyrrolidone (NMP) and DCM three times each and the first amino acid was coupled using
HCTU and DIEA in NMP (4 equiv of Nα-Fmoc amino acid, 4 equiv of HCTU , and 8 equiv of
DIEA). The double coupling was performed at all steps under the same coupling condition due to
the sequence deletion and slower coupling rate in longer sequences. After coupling, the resin was
washed with NMP (× 3)and DCM (× 3) and any unreacted free amine groups on the resin were
treated using 50 % acetic anhydride in pyridine for 5 min. After the resin was washed with NMP
(× 3) and DCM (× 3), the same procedure was repeated for the next amino acid coupling until
every residue was coupled.
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5.2.2 Alloc Deprotection
The Alloc protecting group of C-terminal Lys was deprotected with piperidine (5-10 drops) and
Pd(PPh3)4 (0.2 equiv) in anhydrous chloroform. Under the nitrogen gas, the reaction mixture was
stirred for 15 min then repeated. After the resin was washed with chloroform, NMP and DCM,
the following sequence D-Glu-D-Glu-DOTA was coupled to the free amine via HCTU coupling
as described above.

5.2.3 Cleavage of Peptide from the Resin
The peptide and protecting groups were cleaved using cleavage cocktail (88 % Trifluoroacetic
acid (TFA), 5 % water, 5 % phenol, and 2 % triethylsilane) for 4 h. The crude peptide was
isolated from the resin by filtration, the filtrate was concentrated, and the peptide was
precipitated in ice cold diethyl ether, dissolved in water, and lyophilized. The off-white crude
powder was purified by reverse-phase chromatography. See Figure 20.

Figure 20. Scheme showing synthetic route to metal chelation.

The complexation of 225Ac with DOTA-di-D-Glu-MC1RL was performed identically to what has
been previously described for previously described for 225Ac-DOTA-Ahx-MC1RL.76
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5.2.4 Radiosynthesis of 225Ac Radiopharmaceutical
Radiochemical synthesis and characterization of 225Ac-DOTA-Ahx-MC1RL was
performed as previously described.76

5.2.5 Animal Studies
A375 and A375/MC1R human cutaneous melanoma cells were obtained and grown as
before.118
Two groups of 16 severe combined immunodeficient (SCID) mice bearing A375 and
A375/MC1R bilateral xenograft tumors (189-1680 mm3) were intravenously administered 148
kBq (±10%) of Ahx or di-D-Glu. After injection, 4 groups (n=4) were euthanized at 24, 96, 144
and 288 hour time points for each cohort. Tumors and 11 other organs including: blood, bone,
brain, heart, intestine kidney, liver, lung, muscle, skin, and spleen, were harvested at each time
point. Activities were determined for organs as described previously.76 Briefly, isomeric gamma
spectra were acquired using a 4π well-type wipe-test gamma scintillation detector (BioDex
Atomlab 500). Activities were calculated using factors for gamma ray abundance per alpha
decay using calibration parameters and correction coefficients from Appendices A and E of the
instrument manual.92 A full energy window (0-800 keV) was used for spectra acquisition that
included gamma counts from 225Ac (99.8 keV peak, 1% abundance).130 The alpha activities were
determined by fitting the 225Ac peak with a Gaussian fit and integrating to determine the net
number of counts while incorporating the acquisition time of 30 seconds. BD was then reported
as percent injected activity per gram (%IA/g). Time activity curves were then calculated for each
organ. A 5-compartment PK model was built with the following compartments: blood, tumor,
normal tissue, kidney, and liver (Figure 21 A).
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Figure 21. A) Schematic of the multi-compartmental pharmacokinetic model. B) The system of
ODE’s that represent the change in compartmental radioactive concentrations.

This model is characterized by a system of 5 ordinary differential equations (ODE’s) using mass
action kinetics which describe uptake, inter-compartmental transitions and clearance rates
(Figure 21 B). 𝐶𝑖 represents radioactive volume concentration in different compartments in
Bq/mL. The 𝐶𝑛𝑜𝑟𝑚𝑎𝑙 compartment represents the sum of radioactive volume concentrations in
non-clearance and non-MC1R specific tissues. 𝑘𝑡𝑖 , 𝑘𝑡𝑜 , 𝑘𝑛𝑖 , 𝑘𝑛𝑜 , 𝑘𝑘𝑖 , 𝑘𝑘𝑜 , 𝑘𝑙𝑖 , and 𝑘𝑙𝑜 are the
forward and reverse first order transfer rate constants for the tumor, normal tissue, kidney, and
liver compartments, respectively. 𝑘𝑘𝑒 , and 𝑘𝑙𝑒 are the first order elimination rate constants from
the kidney and liver compartments. A bolus injection was assumed at time zero in the 𝐶𝑏𝑙𝑜𝑜𝑑
compartment. Using Matlab, the ODE’s were simultaneously numerically solved and fit to
experimental time activity curves using a genetic optimization algorithm.
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5.3 Results
5.3.1 Biodistribution
The time activity curves and biodistribution data were generated and can be seen in Figure 22
and Figure 23 respectively.

Figure 22. Time activity plots generated for A) Ahx and B) di-D-Glu

Figure 23. Biodistribution results for A) 225Ac-DOTA-Ahx-MC1RL and B) 225Ac DOTA-di-DGlu-MC1RL.

Both compounds have minimal distribution to organs at risk other than kidney and liver, which
are clearance. The Ahx and di-D-Glu had similar kidney uptake at 24 hours of 4.01 %IA/g and
5.33 %IA/g respectively. The di-D-Glu however had much lower uptake at 24 hours in the liver
at 1.55 %IA/g compared to 11.49 %IA/g for the Ahx.
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5.3.2 Pharmacokinetic Analysis
The fitting of the model solutions to the experimental Ahx biodistribution and di-D-Glu
biodistribution data with optimization by the genetic algorithm can be seen in Figure 24 and
Figure 25 respectively.

Figure 24. Optimized fitting of compartment solution: Ahx. Note: Compartments were solved
and fit simultaneously but plotted separately for visualization.
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Figure 25. Optimized fitting of compartment solution: di-D-Glu. Note: Compartments were
solved and fit simultaneously but plotted separately for vizualization.

The calculated pharmacokinetic transfer and elimination rates for investigated compounds can be
seen in Table 7.
Table 7. PK parameter estimates. All values are [1/hour].
Compound

kti

kto

kni

kno

kki

kko

kke

kli

klo

kle

Ac-DOTA-Ahx-MC1RL

0.0031

0.0008

0.0130

0.0025

0.0034

0.0035

0.0008

0.1193

0.0227

0.0002

Ac-DOTA-di-D-Glu-MC1RL

0.0026

0.0003

0.0010

0.0057

0.0015

0.0071

0.0002

0.0022

0.0081

0.0001

225
225

All of the calculated PK parameter estimates had less than 5% error. From these data, the Ahx
showed larger and faster uptake in the liver. Both compounds had comparable uptake and
clearance rates for other compartments.
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5.4 Discussion
Several multi-compartment pharmacokinetic models have successfully been designed for
therapeutic radiopharmaceutical analysis; however these have been limited to applications using
beta emitters.153-157 In this work, the biodistribution and pharmacokinetic behavior for two
targeted alpha-emitting radiopharmaceuticals targeted to MC1R were investigated.
Both Ahx and di-D-Glu were preferentially taken into high expressing MC1R tumors
while negligibly taken into non-clearance organs and low expressing MC1R tumors. While the
liver showed large uptake of Ahx at 24 hours, these values rapidly decreased to negligible levels
by the final timepoint. Although lower, the di-D-Glu remained nearly constant in the liver during
the course of the study. Both compounds showed similar renal uptake at 24h hours, however Ahx
was more rapidly eliminated from the kidney. Two other peptide MC1R targeted alpha therapies
have been developed and tested in vivo, 212Pb-DOTA-Re(Arg11)CCMSH, and [212Pb]DOTAMC1L.71,158 In the study of both of these compounds, relatively large concentrations of activities
were found in the kidneys and varying degrees of nephrotoxicity were observed. In the current
study, neither Ahx, nor di-D-Glu treatment resulted in renal toxicity.
A PK model was previously developed to analyze the PK of the MC1RL conjugated to a
near infrared fluorescent dye.149 The model from that study was adapted for analysis of the
targeted alpha therapy described in this work. The findings of the biodistribution analyses were
reflected in the optimized fitting of the multi-compartment pharmacokinetic model. When the
obtained transfer and elimination rates were input into the model, the resulting fits to
experimental data agreed with less than 5% error. The liver uptake rate for the Ahx derivative
was calculated to be >5 times larger than the intercompartmental transfer rate and 600 times
greater than the elimination rate. The decrease in activity in the liver then is a result of physical
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radioactive decay with a small portion being returned to the blood compartment. It was
previously shown through histology studies, that despite the large uptake in the liver for the Ahx
compound, no remarkable damage was observed.76
On the other hand, solutions for the di-D-Glu derivative showed much slower uptake, of
about 50 times less than the Ahx, and much slower reverse transfer rate. This is in agreement
with the BD analyses. The calculated MC1R tumor uptake rates were similar between the
compounds. The reverse transfer rate for each was much slower indicating favorable long
residence times in these tissues. The PK calculations indicate that since there are comparable
distributions of radioactivity between the compounds, with much less liver uptake for di-D-Glu,
the injected dose of this derivative could possibly be increased to increase the uptake into MC1R
positive tumor tissues without toxicity.
In conclusion, the two targeted alpha therapies tested in this study, 225Ac-DOTA-AhxMC1RL and 225Ac-DOTA-di-D-Glu-MC1RL showed favorable uptake into MC1R positive
tissues with no toxicity to other organs of interest. Since the multi-compartment model’s
solutions agreed with the measured biodistribution data with low error, therapeutic optimizations
can be considered. The kidney and liver have been identified as the primary dose limiting organs
for the two derivatives. The PK model can be used to simulate the uptake rates and accumulation
rates, clearance rates, and absorbed radiation doses to the organs of interest for varying initial
injection activities and multiple dosing regimens. The model could be used alongside a
companion imaging agent to predict biodistribution for patient specific treatment planning. This
analysis will aid in the accurate prediction of the effectiveness of the therapies in patients.
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CHAPTER SIX:
DEVELOPMENT OF A THREE DIMENSIONAL VOXEL-BASED MONTE CARLO
RADIATION DOSIMETRY METHODOLOGY FOR A TARGETED ALPHA
PARTICLE THERAPY

6.1 Introduction
The goal of this work is to enable individualized 3D voxel based dosimetry of the 225AcDOTA-MC1RL radiopharmaceutical. While there are detectable gamma emissions in the 225Ac
decay chain, SPECT/CT acquisition times required to obtain acceptable counting statistics as a
result of low gamma emission abundance would be unrealistic in the clinical setting. Therefore, a
companion imaging tracer needs to be developed with comparable BD properties and
computational methods need to be developed to convert tracer activity measured to alphaemission activities from the 225Ac decay chain, followed by dose calculations. In the case of the
225

Ac-DOTA-MC1RL radiopharmaceutical, 67Ga is an ideal SPECT imaging tracer for the voxel-

based dosimetry application, as it is chemically similar to 225Ac in terms of charge, is readily
chelated by DOTA and has a long 3.26 d half-life so that longitudinal post-administration
acquisitions can be made. MCNP was used to calculate the volume-specific absorbed dose of the
67

Ga-DOTA-MC1RL tracer. Corresponding ex vivo 67Ga-DOTA-MC1RL and 225Ac-DOTA-

MC1RL BD/PK activity measurements and MIRD-calculated dosimetry data from the same
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animal models and time-points were then used to optimize the simulations and evaluate its
accuracy.

6.2 Materials and Methods
6.2.1 Biodistribution and Mean Organ Dosimetry Studies
Sixteen SCID mice were intravenously injected with 18.5 Mbq of 67Ga-DOTA-MC1RL
in the syringe. The method of net injected activity determination was conducted as described for
225

Ac-DOTA-MC1RL. Three groups (n=4) were euthanized at 24, 48, and 96 hour time points.

Thirteen organs were harvested at each time point. Organ activities were determined using the
Biodex scintillation detector. Spectra were obtained and fitted with multi Gaussian fits. The
computational model of the NaI(Tl) detector described in Section 2.1.2 was used to simulate the
67

Ga gamma spectrum and determine the detector correction factor. The activity at each

timepoint was calculated by integrating each photopeak, applying the corresponding detector
efficiency and abundance at the energy of each photopeak, and summing. The activities at each
time point were averaged, and the biodistribution was calculated and presented a %IA/g. Tissue
BD data for the different tissues were fitted using an exponential decay nonlinear regression and
mean absorbed dose calculations were performed using the MIRD methodology.46 Since 67Ga is
a gamma emitter, the assumption that all emissions remain in source location fails and absorbed
fractions need to be considered.159 Monte Carlo pre-calculated S-values obtained from the Mouse
Whole-Body (MOBY) phantom for 67Ga were used to in these calculations.160 The absorbed dose
in each target organ was calculated as the summation of contributions from all source organs,
including the target organ as a source organ.
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6.2.2 Development of Voxel-Based Dosimetry
6.2.2.1

CT to MCNP Conversion Algorithm
In order to develop the voxelized dosimetric algorithm, a preliminary CT dataset was

acquired on a clinical CT scanner of the Electron Density Phantom (EDP, Sun Nuclear Corp.).
The EDP consists of a zero HU Solid Water® disk the size of an average human pelvis. Sixteen
insert chambers in the disk are designed to be used with interchangeable sets of Tissue
Mimicking Materials (TMM), including 13 different materials with a wide range of electron
density values (lung, breast, zero solid water, liver, brain, inner bone, bone, cortical bone, true
water, adipose, and optional bones with different mineral composition). To inform the MonteCarlo model of the elemental composition of a given volume that corresponds to a specific HU
value, electron densities of specific volumes were linked to HU values determined in the TMM’s
and HU-ED calibration curves were generated. EDP inserts have well known electronic densities
and material composition. A material library containing elemental composition and electron
densities was created. ROIs in the phantom CT images were contoured using Mirada Medical
software. The external boundary of the whole EDP was also segmented so that radiation dose to
the rest of the phantom can be calculated and the photon and electron scattering will be properly
simulated.
The CT dataset and DICOM tags were read and stored using MATLAB. MCN6.2 has the
capability to define repeated structures as a lattice. The lattice defines an array of indexed
hexahedra prisms that can fill any structure in the geometry. Lattice elements with similar
properties, such as materials can be grouped together into “universes”. Therefore, the geometry
of the entire CT dataset can be defined using several DICOM tags found in the headers of the
CT. The ImagePositionPatient tag defines the Cartesian coordinate of the center of the upper-left
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most voxel of the first slice of the dataset. PixelSpacing and SliceThickness define the
dimensions of each voxel, while Height, Width, and Slices define the number of voxels in the x,
y and z directions in the dataset. Using these tags, the boundaries of the dataset were defined in
MCNP which was then filled with a lattice describing the voxels.
The dataset was stored in MATLAB as a 3D matrix where each element is a voxel
containing its grayscale intensity value. To interpret these intensities in a physical manner, the
values were linearly transformed to Houndsfield Units (HU) using the RescaleSlope and
RescaleIntercept DICOM tags. The HU scale was segmented in to ranges that represent the
radiodensities of the TMM of the EDP phantom.161 The material definitions are shown in Table
8.
Table 8. The materials and corresponding densities and elemental compositions used in
dosimetric calculations.162

ID

Material

HU Range

1
2
3
4
5
6

Air
Lung
Fat
Water
Muscle
Bone

<-800
-799 – -200
-199 –50
-49 – 50
50 -280
>281

Density
(g/cm3)
0.001225
0.26
0.9
1
1.05
1.6

H
(Z=1)
0.103
0.114
0.111
0.102
0.034

C
(Z=6)
0.105
0.598
0.143
0.155

N
(Z=7)
0.755636
0.031
0.007
0.034
0.042

O
(Z=8)
0.231475
0.749
0.278
0.889
0.71
0.435

Chemical Composition (% by mass)
Na
Mg
P
S
(Z=11) (Z=12) (Z=15) (Z=16)
0.002
0.002
0.003
0.001
0.001
0.001
0.001
0.002
0.003
0.001
0.002
0.103
0.003

Cl
(Z=17)
0.003
0.001
-

Ar
(Z=18)
0.012842
-

The entire CT dataset was defined as integer values representing each material. Each element of
the same material designation was defined as a universe, which then filled the defined lattice.
The geometrical and material definitions were written to a file compatible for MCNP input.

6.2.2.2

ROI Extraction Algorithm
After the CT dataset was acquired, each TMM was segmented into 13 regions of interest

(ROI’s) in Mirada. The resulting DICOM structure set (RTSS) file was imported into MATLAB.
This file contains the series of points in Cartesian space that define each ROI on each CT slice.
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K
(Z=19)
0.002
0.004
-

Ca
(Z=20)
0.225

An affine transformation was applied to map the points of each ROI to specific voxels of the
corresponding CT dataset.

Figure 26. Affine transformation to map to voxel location. Pxyz are the Cartesian coordinates of
the voxel, Sxyz are the Cartesian coordinates of the voxel in the top left corner of the dataset, ijk
are the voxel indices, Δijk are the pixel spacing and slice thickness, and XYZ define the
directional cosines.
A binary mask was applied to each voxelized ROI with the parameter that if greater than half of
a given voxel was covered by the line of shortest distance between neighboring points, that voxel
would return true.

6.2.2.3

SPECT to MCNP Conversion Algorithm
The absolute activity quantification must be determined for a particular SPECT system

and isotope to perform image based internal dosimetry. This calibration factor is used to convert
the reconstructed SPECT voxel values to activity.163 A 5 mL polyethylene sphere was filled with
activity of 67Ga and measured in the Biodex ion chamber. SPECT images were immediately
obtained of the filled sphere in air using the Siemens Inveon two head SPECT scanner with 5MWB-1.0 collimators. The SPECT data were reconstructed using the OSEM3D reconstruction
algorithm with the point spread function model. Effective isotropic voxel size was 0.5 mm. The
dataset was imported into Mirada where the sphere was contoured into an ROI. The ROI
extractor was used to voxelize the ROI and sum the SPECT values within the volume. The
absolute activity calibration factor (in units of Bq/counts) was determined by dividing the
activity measured in the ion chamber by the sum of the SPECT voxel values. This value was
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applied to all voxels in the dataset. The indices of each element and corresponding activity value
of the dataset were then incorporated into the voxelized source definition of the MCNP input.

6.2.3 In vivo Imaging Studies
After developing the image conversion algorithms using the phantom studies, a clinically
translatable workflow was designed (Figure 27).

Figure 27. The clinical workflow to perform patient 3D specific dosimetry.

This workflow was applied to a preclinical in vivo experiment described below.

µSPECT/CT images were acquired for three SCID mice at 24, 48, and 96 hour time
points. CT images were obtained using the Siemens Inveon conebeam CT scanner. Effective
pixel resolution was 88.0 µm. CT data were reconstructed using Siemens’ OSEM3D
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reconstruction protocol with no binning. SPECT images were obtained using the Siemens Inveon
two head SPECT scanner with 5-MWB-1.0 collimators. SPECT data were reconstructed using
the OSEM3D reconstruction algorithm with point spread function model. Effective isotropic
voxel size was 0.5 mm. The CT and SPECT datasets were registered manually using Mirada.
The CT dataset was then resampled to match the 120x120x240 matrix size of the SPECT dataset.
ROI’s for the kidneys, liver, and external were created for each mouse. The ROI extraction
algorithm was employed and the whole organ SPECT-calculated 67Ga activity was compared to
measurements in the ion chamber. For each time point, the CT and SPECT conversion
algorithms were executed to generate the MCNP input. A full Monte Carlo run was performed
for each time point with all 67Ga gamma emissions above 0.5% abundance defined. Detailed
photon physics treatments were employed. The detailed physics treatment includes coherent
scattering, fluorescent photons post photoelectric absorption, and Compton profiles to account
for electron binding effects91. Secondary electrons were produced but assumed to deposit their
energy locally using the thick target bremsstrahlung model. Energy deposition (F6) tallies were
placed in every voxel in the geometry within the external contour. The Monte Carlo generated
dose rate maps for 67Ga-DOTA-MC1RL were integrated to obtain total absorbed dose. This was
compared to total body absorbed dose calculated using the MIRD fixed geometry schema.
Therapeutic absorbed dose was calculated for 225Ac in the kidneys, liver, and total body.
The 67Ga-to-225Ac activity conversion was performed using the SPECT derived activity per voxel
and assuming that the number of 67Ga atoms was equal to the number of 225Ac atoms at each
location in the geometry:
𝐴225𝐴𝑐 = 𝐴67𝐺𝑎
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𝜆225𝐴𝑐
𝜆67𝐺𝑎

Equation (9)

resulting in a 3D 225Ac activity map. Monte Carlo simulations were performed for the entire
spectrum of 225Ac alpha particle emission. Alpha particles were tracked with the FermiLab
angular deflection model with Vavilov straggling.91 Delta ray production was turned on with and
tracked with a 1 keV energy cutoff. Bremsstrahlung production and transport were turned on also
with a 1 keV energy cutoff. The alpha particle tracking energy cutoff was set to 10 keV.
Absorbed dose calculations were performed for the total body for 67Ga and 225Ac for each time
point. Voxelized organ absorbed dose simulations were also performed for 225Ac-DOTAMC1RL considering only each specific organ resulting in absorbed dose rates at each time point.
The dose rates were fitted with exponential nonlinear regression and integrated to obtain the total
absorbed dose in each voxel. The image based mean absorbed dose in each organ was compared
to the MIRD mean absorbed doses previously calculated. Dose volume histograms (DVH) were
generated to analyze the 3D dose distributions. All Monte Carlo simulations were performed on
the high performance computing cluster at Moffitt Cancer Center. The number of histories for
each simulation was chosen to give tally errors of less than 10% in each voxel.

6.3 Results
6.3.1 Biodistribution and Mean Organ Dosimetry
The computational Monte Carlo model of the NaI(Tl) detector described in Chapter III
was used to simulate the 67Ga gamma spectrum and determine the detector correction factor
(Figure 28 A). The gamma spectrum fitting algorithm was applied to acquired 67Ga
measurements (Figure 28 B).
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Figure 28. A) Monte Carlo simulated gamma spectrum of 148 kBq of 67Ga. B) Representative
gamma spectrum and fitting of 67Ga acquired with the NaI(Tl) scintillation detector.

The NaI(Tl) correction factor was determined to be 5.65. The harvested organs were measured in
the NaI(Tl) detector and activities determined using the spectrum fitting algorithm. The
biodistribution is shown in Figure 29.
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Figure 29. Biodistribution of 67Ga-DOTA-MC1RL.

The tissue BD data were fitted using an exponential nonlinear regression and integrated in order
to obtain the cumulated activity in each organ. Using the pre-calculated S values from the
MOBY phantom and the MIRD schema, estimations for mean organ absorbed doses were made
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(Figure 30).

Figure 30. Mean 67Ga-DOTA-MC1RL absorbed dose.

88

6.3.2 Phantom SPECT/CT imaging
CT images of the EDP phantom were acquired with a matrix size of 512x512x28 (Figure
31). Contours were manually drawn around all 13 TMM’s and the external on each relevant
slice.

A

B

C

Figure 31. Electron Density Phantom. A) CT-image of middle axial slice, B) visible light image
and C) segmented CT image.

Using the CT to MCNP algorithm, the EDP dataset was converted from DICOM format to the
MCNP lattice geometry (Figure 32 A). The voxel values were replaced with material/universe
integer ID values.

Figure 32. A) The MCNP converted EDP dataset. B) The TMM ROI’s in voxel coordinates.
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The ROI extraction algorithm was implemented on the segmented EDP dataset (Figure 32 B).
The absolute activity quantification was determined for the Inveon scanner with 67Ga.
The Biodex ion chamber reading of the 67Ga activity filled sphere was 234.95 kBq. SPECT
images of the sphere were acquired and segmented creating an ROI (Figure 33). The ROI
extraction algorithm was applied and the total counts within the voxels of the ROI were 9339018
counts. The resulting activity calibration was 0.0252 Bq/count.

Figure 33. Sphere filled with known activity. SPECT images were acquired and used to
determine the absolute activity calibration factor for the scanner.

6.3.3 In vivo Imaging Studies
Three mice were injected with 18.5 MBq of 67Ga-DOTA-MC1RL in the syringe.
SPECT/CT’s were acquired at 24, 48, and 96 hour timepoints. The CT datasets were
downsampled to match the resolution of the SPECT datasets. The SPECT datasets were then
manually registered to the CT datasets. ROI’s were drawn for the kidneys, liver and external on

90

the CT (Figures 34, 35, 36). The ROI extraction algorithm voxelized the ROI’s and converted
them into a format readable by MCNP.

Figure 34. Coronal CT slice of mouse with manually drawn kidneys and liver. The external
contour was generated by thresholding.

Figure 35. Kidneys and liver volumes in voxel coordinates.
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Figure 36. Coronal views of SPECT/CT images acquired A) 24 hours, B) 48 hours, and C) 96
hours post injection of 18.5 MBq of 67Ga-DOTA-MC1RL in SCID mice.

The SPECT-based activity was determined by calculating the total activity in each ROI. These
values were compared to whole organ activity measured in the ion chamber (Table 9). The image
based activity calculations generally underestimated the ion chamber measurements. For the ion
chamber kidney measurements it was assumed the activities of the left and right kidneys were
equal as they were measured together.The average percent differences across all three timepoints
for the right kidney, left kidney, liver, and body were 11.46 ± 3.31, 12.14 ± 3.26, 13.59 ± 6.03 ,
and 50.64 ± 10.42% respectively. The percent difference between the methods remained less
than ~20% for the organs. The differences in total body activity estimations was large reaching
up to 63% difference at the 96 hour timepoint.
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Table 9. The SPECT derived ROI activities compared to organ activities measured using the ion
chamber.

SPECT Activity (kBq)
IC Activity (kBq)
% Difference

Kidney_R
23.45 ± 10.81
25.90 ± 2.59
9.48
Kidney_R

SPECT Activity (kBq)

17.93 ± 11.77

IC Activity (kBq)
% Difference

15.55 ± 1.55
15.28

SPECT Activity (kBq)
IC Activity (kBq)
% Difference

Kidney_R
6.58 ± 9.97
6.01 ± 0.60
9.61

24 hrs
Kidney_L
22.44 ± 8.33
25.90 ± 2.59
13.38
48 hrs
Kidney_L
13.28 ±
10.68
15.55 ± 1.55
14.60
96 hrs
Kidney_L
5.50 ± 8.42
6.01 ± 0.60
8.44

Liver
136.00 ± 9.49
120.95 ±12.09
12.44

Body
254.02 ± 4.55
444.00 ± 4.44
42.79

Liver

Body

59.73 ± 9.25

166.24 ± 4.85

65.08 ± 6.51
8.22

311.73 ± 31.17
46.67

Liver
29.73 ± 9.51
37.21 ± 3.72
20.12

Body
150.67 ± 3.75
401.45 ± 40.15
62.47

The CT to MCNP conversion algorithm was performed on the three datasets. The defined
materials were air, lung, fat, water, muscle, and bone. The SPECT to MCNP conversion
algorithm was perfomed for the 67Ga-DOTA-MC1RL and the converted 225Ac-DOTA-MC1RL
distributions for the three timepoints. Monte Carlo absorbed dose calculations were performed
for the whole body for both radionuclides at each time point. Voxelized organ absorbed dose
simulations were also performed for 225Ac-DOTA-MC1RL considering only each specific organ.
The converted CT, and corresponding slices of the resulting whole body absorbed dose
distribution from 67Ga-DOTA-MC1RL and converted 225Ac-DOTA-MC1RL can be seen in
Figure 37.
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A)

B)

C)

Figure 37. For 24, 48, and 96 hours: A) Mouse-specific phantom obtained from CT. B) Absorbed
dose map for 67Ga-DOTA-MC1RL. C) Corresponding absorbed dose map for 225Ac-DOTAMC1RL. Note the difference in scales. Spatial dimensions are in centimeters.
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The mean whole body absorbed dose for 67Ga-DOTA-MC1RL was 2.6085E-06 mGy/MBq. This
underestimated the MIRD calculated whole body dose of 4.9E-04 mGy/MBq.
Mean absorbed doses for the right kidney and liver were calculated. Voxelized dose maps for
67

Ga-DOTA-MC1RL and 225Ac-DOTA-MC1RL can be seen in Figure 38.

Figure 38. Absorbed dose maps for 67Ga-DOTA-MC1RL in the right kidney at 24, 48, and 96
hour time points and corresponding dose maps for 225Ac-DOTA-MC1RL. The spatial dimensions
are in centimeters.

The dose rates were fitted with an exponential regression and integrated to obtain the total
absorbed dose to the kidney from 67Ga-DOTA-MC1RL and 225Ac-DOTA-MC1RL (Figure 39).
The mean absorbed dose to the right kidney from 67Ga-DOTA-MC1RL was calculated to be
0.0084 ± 0.0022 mGy/MBq. Using the MIRD schema, the mean absorbed dose to the right
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kidney was found to be 0.0079 ± 0.0016 mGy/MBq (Figure 30). The same procedure was
performed to calculate the mean dose from 225Ac-DOTA-MC1RL to the right kidney.

Figure 39. Exponential fitting of the mean dose rate as a function of time for 225Ac-DOTAMC1RL in the right kidney.

The mean absorbed dose to the right kidney was calculated to be 0.0213 ± 0.0082 Gy/kBq. Using
the MIRD schema, the mean absorbed dose to the right kidney was found to be 0.0150 ± 0.0031
Gy/kBq (Table 5). The DVH for the kidney can be seen in Figure 40.

Figure 40. Dose volume histogram for 225Ac-DOTA-MC1RL in the right kidney.
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The absorbed dose maps for the left kidney can be seen in Figure 41.

Figure 41. Absorbed dose maps for 67Ga-DOTA-MC1RL in the left kidney at 24, 48, and 96
hour time points and corresponding dose maps for 225Ac-DOTA-MC1RL. The spatial dimensions
are in centimeters.

The dose rates were fitted with an exponential regression and integrated to obtain the total
absorbed dose to the left kidney from 67Ga-DOTA-MC1RL and 225Ac-DOTA-MC1RL (Figure
42). The mean absorbed dose to the left kidney from 67Ga-DOTA-MC1RL was calculated to be
0.0075 ± 0.0011 mGy/MBq. This is compared to the MIRD calculated dose of 0.0079 ± 0.0016
mGy/MBq.
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Figure 42. Exponential fitting of the mean dose rate as a function of time for 225Ac-DOTAMC1RL in the left kidney.

Similarly, the voxel-based mean absorbed dose was calculated for 225Ac-DOTA-MC1RL
resulting in 0.0110 ± 0.0002 Gy/kBq as compared to 0.0150 ± 0.0031 Gy/kBq found
conventionally. The DVH can be seen in Figure 43.

Figure 43. Dose volume histogram for 225Ac-DOTA-MC1RL in the left kidney.
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Absorbed dose maps for the liver can be seen in Figure 44.

Figure 44. Absorbed dose maps for 67Ga-DOTA-MC1RL in the liver at 24, 48, and 96 hour time
points and corresponding dose maps for 225Ac-DOTA-MC1RL. The spatial dimensions are in
centimeters.

The mean organ absorbed dose to the liver was calculated for 67Ga-DOTA-MC1RL and 225AcDOTA-MC1RL by fitting the dose at each timepoint with an exponential fit and integrating
(Figure 45).
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Figure 45. Exponential fitting of the mean dose rate as a function of time for 225Ac-DOTAMC1RL in the liver.

The total absorbed dose to the liver from 67Ga-DOTA-MC1RL was 0.0016 ± 0.0001 mGy/MBq.
The MIRD calculated absorbed dose was 0.0031 ± 0.0006 mGy/MBq. The resulting absorbed
dose from 225Ac-DOTA-MC1RL was found to be 0.0633 ± 0.0082 Gy/kBq compared to 0.1485
± 0.0283 Gy/kBq. The dose volume histogram for the absorbed dose in the liver can be seen in
Figure 46.

Figure 46. Dose volume histogram for 225Ac-DOTA-MC1RL in the liver.
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6.4 Discussion
In this work a method was developed to calculate the absorbed radiation dose at the voxel
level for a targeted alpha particle therapy. The companion imaging agent, 67Ga-DOTA-MC1RL,
was developed and tested and compared to the therapeutic agent. Other groups have developed
and used companion imaging agents to perform image-based dosimetry for alpha emitting
radiopharmaceuticals. For example, the 68Ga/225Ac-Prostate-specific membrane antigen-617
(PSMA-617) 70, the 203Pb/212Pb-DOTA-MC1L71, and the
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Tc-methyl diphosphonate/223Ra-

dichloide69 pairs have been used in dose calculations for the targeted alpha therapy of metastatic
castration resistant prostate cancer, metastatic melanoma, and bone metastases respectively.
While this approach results in patient specific prediction of the biodistribution and
pharmacokinetics of the targeted alpha therapy, the treatment planning will be suboptimal.
OLINDA is a model based approach using pre-calculated S factors obtained from a fixed
geometry phantom to calculate mean organ level absorbed dose.
The spectrum fitting algorithm was updated for 67Ga-DOTA-MC1RL biodistribution
analysis using the Monte Carlo detector model that was previously developed. The BD of a
companion imaging agent should ideally mimic the BD of the therapeutic agent in order to
implement a treatment planning procedure. The BD of 67Ga-DOTA-MC1RL and 225Ac-DOTAMC1RL showed that these agents distribute differently throughout the body. At 24 hours, 67GaDOTA-MC1RL showed increased uptake into the kidneys with slightly lower uptake in the liver.
This is much different than the liver uptake of 225Ac-DOTA-MC1RL which was shown to be
nearly 3.5 times greater than kidney uptake at 24 hours. Despite this difference, there was some
uptake into intestine, lungs, and spleen and minimal uptake into other tissues for both 67GaDOTA-MC1RL and 225Ac-DOTA-MC1RL. Dosimetry estimates were performed based on the
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Ga-DOTA-MC1RL BD using the MIRD methodology and fixed geometry S values. Since 67Ga

is a gamma emitter, the assumption that cross organ dose contribution is negligible fails. Using
the S values generated from the standard mouse phantom it was found that the mean dose to the
kidneys was over 5 times greater than the dose to the liver. This is in contrast with the 225AcDOTA-MC1RL calculated dose to the liver which was nearly 5 times greater than the dose to the
kidneys. This discrepancy can be accounted for by applying a factor that corrects the 67GaDOTA-MC1RL biodistribution to that of the therapeutic.
Using the EDP phantom, an algorithm was created that converted acquired CT images
into the MCNP lattice geometry. An algorithm was created that voxelized the segmented ROI’s
drawn around the TMM’s. The EDP phantom has 13 TMM’s however only 6 materials were
modeled in this work. This was necessary because of the complexity of the image derived
geometries and computationally expensive tracking of charged particles through different
materials.
The absolute activity calibration factor was obtained by applying the ROI algorithm to a
spherical phantom filled with 67Ga in air. As a result, the SPECT based organ activity
estimations could be compared to ion chamber based whole organ measurements. The image
based activity estimations for the liver and kidneys agreed with the IC measurements well. The
whole body estimates however were not in agreement with IC measurements with percent
differences of up to ~60%. At all three time points the image based whole body activities
underestimated the ion chamber. A first step to address these differences would be to fill the
spherical phantom with pure 67Ga instead of the whole 67Ga-DOTA-MC1RL compound. This
would allow for uniform activity distribution 67Ga in the phantom and avoid aggregation of the
solution as seen in Figure 33.
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Voxelized absorbed dose maps were successfully generated from the in vivo CT and
SPECT datasets. The whole body absorbed doses did not correlate well with the MIRD
calculations. This was to be expected given the large discrepancies in the image-based activity
estimates and ion chamber measurements. Also, in the conventional calculation of total body
absorbed doses, the assumption is made that the activity not used for organ calculation activity is
uniformly distributed throughout the remainder of the body164.The doses calculated for the
kidneys and liver on the other hand agreed with MIRD calculations to within an order of
magnitude for both 67Ga-DOTA-MC1RL and 225Ac-DOTA-MC1RL. This suggests that the
developed methodology is valid. Discrepancies are likely the result of the many sources of error
in the methodology. The major source is error in activity estimation. ROI’s were drawn manually
on downsampled CT datasets that were manually registered to SPECT datasets. Since the mice
were sacrificed after imaging for tissue harvesting, each timepoint involved a single different
mouse. To reduce error, serial images the same mouse with multiple mice per timepoint should
be performed.
It is evident from the voxel based dose calculations that the uptake of 67Ga-DOTAMC1RL in the liver and kidneys is not uniform. In the case of the kidney, the dose accumulated
more in the outer cortex region. Using the conventional dosimetry formalism, it is not possible to
observe this result. DVH plots are one of the most utilized tools in external beam therapy to
evaluate treatment plan quality. DVH’s were generated for ROI’s with the developed voxelized
methodology enabling capability of volumetric analysis.
Due to the complexity of performing patient specific internal dosimetry, clinical
applications have been limited. Several other voxel-based platforms have been developed,
however the fixed geometry software OLINDA remains the only FDA approved system48. The
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most notable voxel-based systems include 3DRD57, SCMS56, DPM165, VIDA166, and RAPID61.
Similarly to the work presented in this thesis, all of these systems have been benchmarked
against conventional calculations and show good agreement. These systems use the point kernel
convolution method for Monte Carlo simulation and therefore don’t account for tissue
heterogeneities. This method was chosen to make these systems more clinically applicable by
speeding up the calculation, however, none have seen wide acceptance for clinical use. The
methodology developed in this thesis performs full Monte Carlo calculations by tracking all
relevant particles accounting for material compositions. The length of time to perform a full dose
calculation, including all pre and post processing, at a single time point takes ~30 hours. This is
faster than the all the aforementioned platforms. This is noteworthy because these platforms have
mostly been used for photon dose calculations, while the methodology developed here tracks and
tallies not only alpha particles, but delta rays and resulting bremsstrahlung productions. While
several fundamental aspects of the methodology developed here align with these systems, this is
the only one specifically designed to perform targeted alpha therapy dosimetry.
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CHAPTER SEVEN:
CONCLUSIONS

In this work, an alpha emitting radiopharmaceutical was thoroughly assessed. Methods
for improving the accuracy of alpha particle radioactivity determination were developed. This is
important for pharmacokinetic evaluation and patient safety as many aspects of activity
measurement have been overlooked both pre-clinically and clinically. The alpha therapeutic,
225

Ac-DOTA-MC1RL, was tested in several experiments and was shown to have low toxicity,

rapid blood clearance, uptake into MC1R positive tumors and clearance organs, significant tumor
and metastasis growth delay, and prolonged survival in human uveal melanoma xenograft
models in mice following a single administration. Conventional radiation dosimetry analysis
showed 10x greater absorbed doses in high MC1R expressing tumors than in low MC1R
expressing tumors as well as low doses to non-clearance organs. A multi-compartment
pharmacokinetic model was developed with the aim of increasing the personalization of the
treatment by optimizing administration activities for the patient and predicting biodistribution
through the use of a companion imaging agent. Ultimately, the goal of this work was to develop
a patient specific image based dosimetric methodology for 225Ac-DOTA-MC1RL treatment
planning. Most therapeutic radiopharmaceutical therapies use fixed administrations with no
personalization. A companion imaging agent, 67Ga-DOTA-MC1RL was developed and tested.
67

Ga-DOTA-MC1RL has somewhat similar biodistribution to 225Ac-DOTA-MC1RL allowing
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for the visualization and prediction of the spatial and temporal distribution that the therapeutic
will have. By acquiring several SPECT images post administration of 67Ga-DOTA-MC1RL,
cumulated voxelized activity maps can be generated, converted to 225Ac-DOTA-MC1RL activity
and submitted for Monte Carlo dose calculation. The result is a voxelized 3D absorbed dose
distribution. This information can then be used to optimize a treatment plan for patients with the
goal of improving their outcome.
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